Include_ct,Include_js,Decision,Consensus_notes,Scientific_title,Interventions,url,Public_title,Source_registry,TrialID,Date_registration_format,Date_enrollment_format,Day_inferred,Study_type,Study_design,Phase,Target_size,Primary_sponsor,Countries,Conditions,Bridging_flag,Retrospective_flag,Date_registration,Date_enrollment,Last Refreshed on,Acronym,Date registration3,Export date,Source Register,Recruitment_status,other records,Inclusion agemin,Inclusion agemax,Inclusion gender,Contact Firstname,Contact Lastname,Contact Address,Contact Email,Contact Tel,Contact Affiliation,Inclusion Criteria,Exclusion Criteria,Primary outcome,results date posted,results date completed,results url link,Bridged type,results yes no,Date_registration3_format
0,1,NA,NA,"A Pilot Study To Assess The Efficacy Of AYUSH - 64 In COVID - 19 Cases

","Intervention1: Ayush-64, a polyherbal formulation.<br>: The composition of AYUSH 64 includes aqueous extract of Saptaparna (Alstoniascholaris R. Br.) Katuki (Picrorhizakurroa Royle ex. Benth), Kiratatikta (SwertiaChirataPexbex. Karst) and powder of Kuberaksha (Caesalpinia crista Linn.) in the ratio of 1:1:1:2.Dose:- 2 Tablets (500 mg) thrice daily (2-2-2)<br>Dosage form:-	Tablet<br>Route of Administration:-	Oral<br><br>Time of Administration:-after food<br><br>Anupana:- Warm water<br> 	<br>Duration of therapy:- 14 days <br><br>Control Intervention1: Not applicable: Not applicable<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43949,"Efficacy of AYUSH-64 (a polyherbal formulation) in COVID - 19 Cases
",CTRI,CTRI/2020/05/025335,2020-05-24,2020-06-20,FALSE,Interventional,"Single Arm Trial
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable",Phase 3,40,Central Council for Research in Ayurvedic Sciences CCRAS,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,24-05-2020,20-06-2020,2 December 2020,NA,20200524,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr N R Singh,NA,"CBPACS, Khera Dabar, Najafgarh New Delhi 110073 Additional Director office, room no G-31, CBPACS, Khera Dabar, New Delhi 110073",addl.director.academics@gmail.com,9560659728,"Chaudhary Bahm Prakash Ayurved Charak Sansthan, New Delhi","Inclusion criteria: Mild to moderate cases registered in CHC CBPACS above 18 years of age, with COVID 2019 (Confirmed by RT-PCR)  <br/ ><br>Participants who can take medicines orally <br/ ><br>Patients willing to provide signed informed consent <br/ ><br>","Exclusion criteria: Cases of severe vomiting which would make oral administration of medicine difficult. <br/ ><br>Cases of respiratory failure and requiring mechanical ventilation. <br/ ><br>Alanine Transaminase (ALT) or Aspartate Transaminase (AST)  > 2 times the upper limit of normal. <br/ ><br>Patients with COVID 19 in critical condition or ARDS or NIAD 8 â??point ordinal score 2  Hospitalized, on invasive mechanical Ventilation or extra corporeal membrane oxygenation  <br/ ><br>Pregnant or lactating women <br/ ><br>Any other condition, which as per the investigator would jeopardize the outcome of the trial. <br/ ><br>",a) Mean time (days) for clinical recovery as per clinical recovery criteria defined below <br/ ><br>b) Number of patients showing â??clinical recoveryâ?? <br/ ><br>Timepoint: Baseline <br/ ><br>Day 8 <br/ ><br>Day 15,NA,11/08/2020,NA,NA,NA,2020-05-24
0,1,NA,NA,Study on traditional Chinese Medicine intervention Program of COVID-19 's convalescence and sequelae based on COVID-19 case Registration system,Jiexingjunzi granule group:Jiexingjunzi granules;Qibei Fuzheng granule formation:Qibei Fuzheng granule;,http://www.chictr.org.cn/showproj.aspx?proj=62250,Study on Traditional Chinese Medicine Intervention Program for the Sequela of novel coronavirus pneumonia (COVID-19),ChiCTR,ChiCTR2000038740,2020-09-30,2020-08-01,FALSE,Interventional study,Parallel,0,Jiexingjunzi granule group:100;Qibei Fuzheng granule formation:100;,Beijing University of Chinese Medicine Third Affiliated Hospital,China,Novel Coronavirus Pneumonia (COVID-19),FALSE,No,2020-09-30,2020-08-01,9 November 2020,NA,20200930,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,NA,NA,Both,Chengxiang Wang,NA,"51 Xiaoguan Street, Andingmenwai, Chaoyang District, Beijing, China",wang601@vip.sina.com,+86 18612922358,Beijing University of Chinese Medicine Third Affiliated Hospital,"Inclusion criteria: 1. Patients who meet the recovery period of new coronavirus pneumonia;<br>2. Syndrome differentiation is of Qi and Yin deficiency type; <br>3. Informed consent to this study, voluntarily participate in clinical research; <br>4. Can provide detailed contact information, have no short-term relocation wishes, and are willing to cooperate with follow-up.","Exclusion criteria: 1. Patients with fasting water due to gastrointestinal bleeding, intestinal obstruction, etc.; <br>2. Those who cannot cooperate with the original severe brain, heart, liver, kidney and hematopoietic system diseases; those with malignant tumors and mental and neurological disorders who cannot cooperate;<br>3. People with allergies or allergic to the components of the research drug; <br>4. People with abnormal liver function and abnormal kidney function.",TCM syndrome score;,NA,NA,NA,NA,NA,2020-09-30
0,1,NA,NA,Evaluation of the effects of Licorice on clinical symptoms and laboratory signs in patients with COVID-19: An open-label randomized clinical trial,"Intervention 1: Intervention group: The standard treatment regimen for COVID-19 based on the Ministry of Health's protocol, including hydroxychloroquine sulfate (Amin Pharmaceutical company, Isfahan) at a dose of 200 mg twice a day, along with a licorice-based herbal medicine (D-REGLIS 380 mg tablets, registration number: 4750956176234914, Irandarouk Pharmaceutical Company) at a dose of 760 mg three times a day for a period of 14 days. Intervention 2: Control group: Standard treatment for COVID-19 based on the Ministry of Health's protocol, including hydroxychloroquine sulfate (Amin Pharmaceutical company, Isfahan) at a dose of 200 mg twice a day for a period of 14 days.",http://en.irct.ir/trial/47990,Effects of Licorice in treatment of COVID-19,IRCT,IRCT20200506047323N2,2020-05-31,2020-05-21,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization method and table of random numbers will be used. If selected number is even, the patient is allocated to treatment group, and if it is odd, the patient is allocated to control group.",3,60,Bandare-abbas University of Medical Sciences,Iran (Islamic Republic of),"COVID-19 disease. <br>COVID-19, virus not identified;U07.2",FALSE,No,2020-05-31,2020-05-21,15 June 2020,NA,20200531,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,no limit,Both,Mohammad Fathalipour,NA,Emam Hossein Blvd,m.fathalipour@hums.ac.ir,+98 76 3371 0406,Bandare-abbas University of Medical Sciences,Inclusion criteria: <br>                Age =18 years<br>                Positive polymerase chain reaction (PCR) test for COVID-19 or/and lung involvement in imaging<br>                Primary clinical symptoms<br>                Hospitalized<br>                Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm<br>,"Exclusion criteria: <br>                Underlying diseases (heart disease, chronic hypertension, severe renal failure, severe liver failure, and thyroid disorders)<br>                Use of warfarin, SSRIs, MAOIs, diuretics, corticosteroids, and antiarrhythmic drugs<br>                History of drug allergy<br>                Pregnancy and breastfeeding<br>",Body temperature. Timepoint: Before intervention and daily during the study. Method of measurement: Thermometer.;Respiratory rate. Timepoint: Before intervention and daily during the study. Method of measurement: Respiratory Count.;Oxygen saturation. Timepoint: Before intervention and daily during the study. Method of measurement: Pulse oximeter.,NA,NA,NA,NA,NA,2020-05-31
0,1,NA,NA,Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora,"Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care;Dietary Supplement: SivoMixx (200 billion);Drug: Azithromycin;Drug: hydroxychloroquine",https://clinicaltrials.gov/show/NCT04366089,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,CT.gov,NCT04366089,2020-04-22,2020-03-26,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).,Phase 2,152,"Roberto Poscia MD, PhD",Italy,"COVID;SARS-CoV 2;Pneumonia, Viral;Coronavirus Infection",FALSE,Yes,22/04/2020,"March 26, 2020",11 May 2020,PROBIOZOVID,20200422,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ;,"Francesco Pugliese, MD, PhD;Francesco Pugliese, MD, PhD;Francesco Pugliese, MD PhD",NA,;f.pugliese@uniroma1.it;f.pugliese@uniroma1.it,;00390649978024;00390649978024,University of Rome Sapienza - Policlinico Umberto I Rome (Italy);,"<br>        Inclusion Criteria:<br><br>          -  Age > 18 years<br><br>          -  Nasopharyngeal swab positive for COVID-19<br><br>          -  COVID-19 stages I - II - III (*1)<br><br>          -  Hospitalization in the Department of Infectious Diseases<br><br>        Exclusion Criteria:<br><br>          -  COVID-19 stages IV - V - VI (*1)<br><br>          -  Hospitalization in Intensive Care Units<br><br>          -  Pregnancy<br><br>          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency<br><br>          -  Patients who deny consent to the proposed treatment<br><br>          -  Inability to provide informed consent<br><br>          -  Contraindications to performing oxygen-ozone therapy<br><br>          -  hyperhomocysteinemia<br><br>          -  favism or thyroiditis<br><br>          -  coagulopathies<br><br>          -  neurodegenerative diseases<br><br>          -  angina (in particular Prinzmetal's angina) or with previous myocardial infarction<br><br>        (*1) Compliant with indications published by:<br><br>        Italian Society of Anesthesia Analgesia Resuscitation and Intensive Care (SIAARTI).<br><br>        Care pathway for the patient with COVID-19.<br><br>        Section 2 - Recommendations for local management of the critically ill patient - Version 2<br><br>        Available on<br>        http://www.siaarti.it/SiteAssets/News/COVID19%20-%20documenti%20SIAARTI/Percorso%20COVID-19<br>        %20-%20Sezione%202%20-%20Raccomandazioni%20per%20la%20gestione%20locale%20-%20Rev%202.0.pdf<br><br>        Last accessed 20/04/2020<br><br>        Posted on 26.03.2020<br><br>        On page 2 of the previous document :<br><br>        ""6 identified stages:<br><br>          -  sick disease - mild COVID-19 (I stage)<br><br>          -  light pneumonia - mild COVID-19 (II stage)<br><br>          -  serious pneumonia - severe COVID-19 (III stage)<br><br>          -  Acute respiratory distress syndrome (ARDS) - critical COVID-19 (IV stage)<br><br>          -  sepsis - critical COVID-19 (V stage)<br><br>          -  septic shock - critical COVID-19 (VI stage)""<br>",NA,Delta in the number of patients requiring orotracheal intubation despite treatment,NA,NA,NA,NA,NA,2020-04-22
1,0,NA,NA,"A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)","A1:Hydroxychloroquine, small dose;A2:Hydroxychloroquine, high dose;B1:Abidol hydrochloride, small dose;B2:Abidol hydrochloride, high dose;",http://www.chictr.org.cn/showproj.aspx?proj=49428,"A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)",ChiCTR,ChiCTR2000029803,2020-02-14,2020-02-20,FALSE,Interventional study,Parallel,0,A1:80;A2:80;B1:80;B2:80;,Renmin Hospital of Wuhan University,China,Novel Coronavirus Pneumonia  (COVID-19),FALSE,Yes,2020-02-14,2020-02-20,25 February 2020,NA,20200214,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,18,60,Both,Zhan Zhang,NA,"99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China",doctorzhang2003@163.com,+86 18062567610,Renmin Hospital of Wuhan University,"Inclusion criteria: 1. 18 years old <= age <= 60 years old when screening, not limited to men and women;<br>2. Who are in close contact with suspected cases, confirmed cases, and positive test of new coronavirus nucleic acid, and those who have not taken effective protection, that is, close contacts;<br>3. Study subjects are willing to be randomly assigned to any designated treatment group;<br>4. Must agree to not participate in another study of study drugs until day 24 of completion of the study.<br>5. Participants volunteered to participate in this study and signed informed consent.","Exclusion criteria: 1. The physician decides that participating in the trial is not in the best interest of the patient, or does not meet any conditions for safe follow-up in the protocol;<br>2. People with heart disease such as cardiac block;<br>3. People with eye diseases such as retina and cornea;<br>4. Severe liver disease (such as Child Pugh score >= C or AST > 5 times the upper limit);<br>5. Pregnancy or breastfeeding, or a positive pregnancy test during the pre-dose check;<br>6. Patients with known severe renal insufficiency (estimated glomerular filtration rate <= 30mL / min / 1.73m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis.",Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus;,NA,NA,NA,NA,NA,2020-02-14
0,1,NA,NA,Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19),"severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;Acute exacerbation NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;",http://www.chictr.org.cn/showproj.aspx?proj=50017,Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19),ChiCTR,ChiCTR2000030170,2020-02-24,2020-02-15,FALSE,Interventional study,Factorial,0,severe NCP group:8;Acute exacerbation NCP group:8;,Shanghai Public Health Clinical Center,China,Novel Coronavirus Pneumonia (COVID-19),FALSE,No,2020-02-24,2020-02-15,25 February 2020,NA,20200224,12/3/2020 5:31:55 PM,ChiCTR,Recruiting,No,50,100,Both,Lu Hongzhou,NA,"2901 Caolang Road, Jinshan District, Shanghai, China",luhongzhou@shphc.org.cn,+86 18930810088,Shanghai Public Health Clinical Center,"Inclusion criteria: (1) Inpatients aged 50 and over, regardless of gender, voluntarily signed informed consent;<br>(2) Persons diagnosed with 2019-nCoV infection: respiratory specimens or blood specimens are tested positive for 2019-nCoV nucleic acid by real-time fluorescent RT-PCR; or respiratory specimens or blood specimens are sequenced for viral genes, which are highly homologous with known 2019-nCoV;<br>(3) Severe NCP group: meets (""New Coronavirus Infected Pneumonia Diagnosis and Treatment Plan (Trial Fifth Edition)"") diagnostic criteria for heavy NCP.<br>(4) NCP group in acute exacerbation period: NCP patients with acute exacerbation period in general to severe and critically severe (for definition of severe and critically severe, see ""Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Fifth Edition)"");<br>Remarks: ""Judgment Criteria for NCP Patients with Acute Exacerbation in General to Severe and Critical Severity""<br>1) Aged 50 years or older;<br>2) Dyspnea (those who inhale oxygen in a mask);<br>3) Combined with basic diseases, such as COPD, diabetes, hypertension, coronary heart disease;<br>4) White blood cell count is less than 4 × 109 / L or has a tendency to decrease continuously;<br>5) Lymphocyte count <1.5x10^9 / L or a trend of continuous decrease;<br>6) Platelet count is less than 150x10^9/L or has a tendency to decrease continuously;<br>7) Hemoglobin has continued to decrease;<br>8) C-reactive protein >=10 mg / L or a trend of continuous increase;<br>9) Procalcitonin >=0.5 ng / mL or a tendency of continuous increase;<br>10) Lactate dehydrogenase >=250 U/L or a trend of continuous increase;<br>11) Aspartate aminotransferase and alanine aminotransferase have a tendency to increase continuously;<br>12) Creatinine >=133 umol/L or a tendency of continuous increase;<br>13) D-dimer >=0.5 mg/L or a trend of continuous increase;<br>14) There is a continuous decrease in serum potassium;<br>15) IL-6 has a tendency to increase continuously;<br>16) Any of IL-2, IL-4, IL-10, TNF, IFN-r, and IL-17A has a tendency to increase continuously;<br>17) Imaging findings consistent with NCP progression.<br>Remarks: (1) If 9 or more of the above 17 items are met, they are judged to be ""normal-to-severe, severely severe NCP patients with acute exacerbation period""; (2) continuous increase or decrease trend: at least 3 consecutive measurements, specific trends Determined by the research doctor; (3) In view of the special circumstances of the NCP, during the trial implementation, the selection criteria of the protocol can be appropriately updated and adjusted according to the clinical progress.","Exclusion criteria: Exclusion criteria for the severe NCP group were the same as those for the acutely exacerbated NCP group:<br>1. Have a history of drug dependence or substance abuse;<br>2. female patients who are pregnant or lactating;<br>3. People with allergies or known allergies to research drugs and excipients;<br>4. In patients with impaired liver function, alanine aminotransferase (ALT) / aspartate aminotransferase (AST) increases more than five times the upper limit of normal;<br>5. Patients with renal impairment (dialysis treatment patients or eGFR <60mL / min);<br>6. Those who meet the diagnostic criteria of ARDS:<br>(1) acute onset;<br>(2) oxygenation index (PaO2 / FiO2) <=200mmHg [1mmHg = 0.133kPa, regardless of the positive end-expiratory pressure (PEEP) level];<br>(3) positive X A chest radiograph showed patchy shadows in both lungs;<br>(4) pulmonary artery incarceration pressure <=18mmHg, or no clinical evidence of increased left atrial pressure.<br>7. Patients with significantly impaired cardiac function: those with A and NYHA heart failure classification = Grade II or LVEF <=lower limit of normal value; those with ECG in leads B and 12 suggesting conduction block or acute myocardial infarction requiring urgent treatment;<br>8. Combining other serious diseases that affect patient survival, such as malignant tumors;<br>9. the use of immunosuppressants or diseases that seriously affect the immune system, such as human immunodeficiency virus infection;<br>10. Combining other infections that are severe and uncontrollable (bacteria, chlamydia, deep fungi, etc.);<br>11. Those with diarrhea> 4 times / day;<br>12. People who have difficulty swallowing oral drugs;<br>13. Situations in which other researchers find it inappropriate to participate in research.",Severe NCP group: Time to clinical improvement (TTCI) [time window: 28 days];Acute exacerbation NCP group: Time to clinical recovery [time window: 28 days] and the ratio of common to severe and critically severe.;,NA,NA,NA,NA,NA,2020-02-24
0,1,NA,NA,"Effect of adjuvant homoeopathy with standard treatment protocol in management of covid-19: a randomised, open label, placebo controlled, parallel  group study

","Intervention1: Homoeopathic medicine: Homoeopathic medicines will be given to this group patients as an add-on to standard treatmet. Following Individualization medicines will be selected keeping in view pathological aspect of disease. Dose and potency will be according to the frequency, intensity and duration of signs and symptoms. Repetitions will vary from cae to case basis cosidering disease state and vitality of patient. Range of potency from 30, 200, 1M etc will be used.<br>Control Intervention1: Placebo: Placebo group patients will receive identical placebo (globules moistened with dispensing alcohol) as an add on to standard protocol treatment. Dose repetition will be a in similar pattern to medicine group.<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43393,Homoeopathy as adjuvant in management of Covid-19 infection,CTRI,CTRI/2020/05/024969,2020-05-01,2020-10-15,FALSE,Interventional,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label",Phase 2/ Phase 3,100,Naiminath Homoeopathic Medical College Hospital and Research Centre,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,01-05-2020,15-10-2020,2 December 2020,NA,20200501,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Anil Khurana,NA,"61-65, Sewa Marg, Opp D Block, Institutional Area, Janakpuri, New Delhi, Delhi 110058 61-65, Sewa Marg, Opp D Block, Institutional Area, Janakpuri, New Delhi, Delhi 110058",drdnayak@gmail.com,09873404012,CCRH,Inclusion criteria: o	Symptomatic RT-PCR confirmed cases of  <br/ ><br>        Covid-19  infection. <br/ ><br>o	Both sexes  <br/ ><br>o	Age between 18 years to 80 years and  <br/ ><br>o	Willing to give signed written informed  <br/ ><br>        consent <br/ ><br>,"Exclusion criteria: 1.	Patients requiring ventilatory support <br/ ><br>2.	Patients with compromised immunity <br/ ><br>3.	Severe heart, lung, kidney, brain, blood  <br/ ><br>        diseases or other important systemic  <br/ ><br>        diseases <br/ ><br>4.	Subjects unable to complete the study, or  <br/ ><br>        not suitable for the study by  <br/ ><br>        researchers. <br/ ><br>5.	Women during pregnancy <br/ ><br>6.	Lactating mothers <br/ ><br>",Clinical outcome in terms of recovery of patient or requirement of life support (ventilator)/ death.Timepoint: Ever 24 hr.,NA,NA,NA,NA,NA,2020-05-01
0,1,NA,NA,"A Randomized, Open Label, Single Centre, Observational, Prospective, Clinical Study to Evaluate the Efficacy and Safety of GanjhuVir syrup and tablet when administered along with Standard of Care (SOC) and compared against SOC in Covid-19 positive patients.","Intervention1: Ganjhuvir Syrup: 10 ml Ganjhuvir syrup will be administered 3 times a day, 1 hr before meal, along with SOC for 10 days<br>Intervention2: Ganjhuvir Tablet: 1 Ganjhuvir Tablet will be administered 3 times a day, 1hr before meal, along with SCO for 10 days.<br>Control Intervention1: Standard of Care treatment: As prescribed and as recomended<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43844,Clinical study to evaluate efficacy and safety of GanjhuVir syrup and tablet in Covid-19 positive patients.,CTRI,CTRI/2020/07/026463,2020-07-09,2020-07-10,FALSE,Interventional,"Randomized, Parallel Group, Multiple Arm Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Not Applicable",N/A,15,Radhika Ayurveda Research and Development,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,09-07-2020,10-07-2020,2 December 2020,NA,20200709,12/3/2020 5:31:55 PM,CTRI,Recruiting,No,NA,NA,NA,Dr Rajesh Kumar Ganjhu,NA,"Radhika Ayurveda Research and Development, RH No.03 Survey No. 1 -1-1 Laxmi Nagar, Pimple Gurav, Pune -411061, Maharashtra, India",rajeshganjhu@gmail.com,NA,Radhika Ayurveda Research and Development,Inclusion criteria: 1. Male or female volunteers aged between 18 to 65 years both inclusive. <br/ ><br>2. Ready to give informed volunteer consent. <br/ ><br>3. Respiratory Syndrome caused by Corona virus infection confirmed by polymerase chain reaction (PCR) test /any other confirmatory tests. <br/ ><br>4. Patient who require hospitalization. <br/ ><br>5. Diabetic patients with sugar levels in normal limits. <br/ ><br>6. Females must be using an effective contraception method or other form of birth control prior to and during the study and use will continue till EOS. <br/ ><br>7. Males will ensure that their female partners of childbearing potential will utilize an effective contraceptive method or other form of birth control to avoid pregnancy. <br/ ><br>,"Exclusion criteria: 1.Previously treated with antiviral therapy, systemic steroids or immunosuppressant within 2 weeks prior to study Day1. <br/ ><br>2. Participation in any other clinical trial of an experimental treatment for Covid-19 or any other clinical trial of different indication. <br/ ><br>3. Hospitalization in ICU. <br/ ><br>4. Evidence of multiorgan failure, suspected latent tuberculosis infection <br/ ><br>5. Requiring mechanical ventilation at screening. <br/ ><br>6. Any known severe allergic/ hypersensitivity to GanjhuVir syrup or tablet. <br/ ><br>7. Patients with chronic kidney disease, cardiac anomaly, receiving cancer therapy, HIV positive or Hepatitis positive. <br/ ><br>8. Females who are pregnant (positive urine or serum pregnancy test at screening evaluation) or lactating. <br/ ><br>9. Presence of any pre-existing illness that, in the opinion of the investigator, would place the subject at an unreasonably increased risk through participation in thisstudy. <br/ ><br>10. Participation in another trial with an investigational drug within 1 month prior to this trial. <br/ ><br>11. Patients who, in the judgment of the investigator, will be unlikely to comply with the requirements of this protocol.","1. Reduction in Covid -19 viral load on day 5 and day10. <br/ ><br>2. Improvement in symptoms like cough, sore throat, fever, inflammation and shortness <br/ ><br>of breath from baseline to 5 and day10 <br/ ><br>3. Changes in platelet, WBC count and C- Reactive Protein from baseline to day 5, and up <br/ ><br>to10 <br/ ><br>4. Number of patients requiring oxygen therapy at the end of the treatment[10 day] <br/ ><br>5. Temperature measurement twice daily at armpit [9 AM and 9PM] <br/ ><br>7Duration of hospitalization: From randomization up to day10. <br/ ><br>Timepoint: Efficacy Assessments from day 0 to day10",NA,NA,NA,NA,NA,2020-07-09
0,1,NA,NA,Effect of Malla Chandrodaya & Ashtadashang ghan vati in Patients with mild to moderate Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections,"Intervention1: Combination of Malla Chandrodaya &<br>Ashthadashang Ghana vati with anupana of Parijata Swaras.: Malla Chandrodayaa 32 mg & Ashtadashang Ghana Vati 500 mg twice daily with anupana of Parijata swaras, oral mode of administration<br>Control Intervention1: Standard care for COVID 19 patients as per Government of India advisory: Drugs advised by Government of India in its advisory for COVID 19 patients<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45105,A clinical trial of Ayurveda formulations in COVID-19,CTRI,CTRI/2020/06/026229,2020-06-29,2020-07-10,FALSE,Interventional,"Non-randomized, Active Controlled Trial
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable",Phase 2,100,Dr Namrata Joshi,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,29-06-2020,10-07-2020,2 December 2020,NA,20200629,12/3/2020 5:31:55 PM,CTRI,Recruiting,No,NA,NA,NA,Dr Namrata Joshi,NA,"Dept. of Rasashastra
Faculty of Ayurveda
IMS,BHU,Varanasi",drnamratajoshi@gmail.com,9319037367,BHU,Inclusion criteria: i. Laboratory-confirmed mild to moderate symptomatic cases of COVID-19 above <br/ ><br>between 18years irrespective of sex will be included. <br/ ><br>ii. Patients able to take medicines orally. <br/ ><br>iii. Patients willing to provide signed informed consent may be included in the Inclusion <br/ ><br>criteria.,"Exclusion criteria: i. Cases of severe vomiting which would affect oral administration of medicine difficult. <br/ ><br>ii. Cases of respiratory failure and requiring mechanical ventilation <br/ ><br>iii. Combined organ failure requiring ICU monitoring. <br/ ><br>iv. Any other condition, which as per the investigator would jeopardize the outcome of <br/ ><br>the trial.",1. All-cause mortality <br/ ><br>2. WHO Ordinal Scale for Clinical Improvement of COVID-19Timepoint: Daily until discharge,NA,NA,NA,NA,NA,2020-06-29
0,1,NA,NA,To Determine the Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients: A Double-Blind Randomized Controlled Trial - RNB,Intervention1: Raj Nirwan Bati capsule: 1. Mercury (Para)<br>2. Sulphur (Gandhak)<br>3. Gold (Sona)<br>4. Silver (Chandi)<br>5. Clamina Perpeta<br>6. Arsenic Trioxide (Hartal Bhasma)<br>7. Black pepper (Kaali Mirch)<br>8. Naag Damanti (Snake Plant)<br>9. Celery (Azwaiyan)<br>10. Zinc<br>11. Niramish (Mahamash oil)<br><br>One Raj Nirwan Bati capsule of 125 mg (1 Ratti) twice a day empty stomach for 12 days<br>Control Intervention1: Placebo: Sugar gelatin capsule<br>with 4 small balls of sugar <br>twice a day empty stomach for 12 days<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44707,Efficacy of An Ayurvedic Preparation Raj Nirwan Bati (RNB) on symptomatic COVID-19 Patients,CTRI,CTRI/2020/06/025998,2020-06-20,2020-06-30,FALSE,Interventional,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Case Record Numbers  Blinding and masking:Participant and Investigator Blinded",Phase 3,60,Uttar Pradesh University of Medical Sciences,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,20-06-2020,30-06-2020,2 December 2020,NA,20200620,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Raj Kumar,NA,"Uttar Pradesh University of Medical Sciences, Saifai, Etawah",nareshpalsingh@gmail.com,09458641119,Uttar Pradesh University of Medical Sciences,"Inclusion criteria: 1.	RT-PCR confirmed SARS-CoV-2 infected symptomatic patients admitted to the COVID-19 hospital of UPUMS <br/ ><br>2.	Patients falling in mild, moderate and severe category of COVID-19 illness <br/ ><br>3.	Patients more than 18 years of age <br/ ><br>",Exclusion criteria: 1.	All critically ill patients of COVID-19 <br/ ><br>2.	Patients not providing informed written consent for the study <br/ ><br>3.	Pregnant and lactating females <br/ ><br>4.	Patients of Chronic kidney disease (CKD) more than stage three <br/ ><br>5.	Asymptomatic cases <br/ ><br>6.	Study participants becoming critically ill during the course of intervention. <br/ ><br>,"Micro-biologically becoming RT-PCR negative for SARS-CoV-2Timepoint: Micro-biologically RT-PCR results for SARS-CoV-2 shall be evaluated at baseline, day 6 and day 12",NA,NA,NA,NA,NA,2020-06-20
1,0,NA,NA,Evaluation of the Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention in COVID-19 Intensive Unit Care Patients.,Drug: Lovenox 40 MG in 0.4 mL Prefilled Syringe;Device: Ultrasound of the lower limbs,https://clinicaltrials.gov/show/NCT04520620,Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention,CT.gov,NCT04520620,2020-07-22,2020-05-02,FALSE,Interventional,Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 4,0,Centre Hospitalier Universitaire de Saint Etienne,France,Sars-CoV2,FALSE,Yes,22/07/2020,"May 2, 2020",31 August 2020,COV-ENOX,20200722,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,NA,"Paul ZUFFEREY, MD",NA,NA,NA,CHU SAINT-ETIENNE,"<br>        Inclusion Criteria:<br><br>          -  Aged > 18 ans<br><br>          -  SARS-CoV-2 infected intensive care unit patients<br><br>          -  Diagnosis of SARS-CoV-2 respiratory infection was made with a nasopharyngeal swab or a<br>             deep respiratory specimen.<br><br>          -  Patient receiving enoxaparin treatment as part of care or as part of a clinical trial<br>             for the prevention or treatment of thromboembolic venous disease.<br><br>          -  Patient affiliated or entitled to a social security scheme<br><br>        Exclusion Criteria:<br><br>          -  Creatinine clearance according to Cockcroft and Gault <30ml/min.<br><br>          -  Hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low<br>             molecular weight heparins (LMWHs)<br><br>          -  History of immune-mediated heparin-induced thrombocytopenia (HIT) in the last 100 days<br>             or in the presence of circulating antibodies<br><br>          -  Active clinically significant bleeding or a condition associated with a high risk of<br>             bleeding, such as a recent hemorrhagic stroke, gastrointestinal ulcer, the presence of<br>             a malignant tumour at high risk of bleeding, recent brain, spinal or ophthalmologic<br>             surgery, known or suspected esophageal varices, arteriovenous malformations, vascular<br>             aneurysm or major intrarachidian or intracerebral vascular abnormalities.<br><br>          -  Spinal, epidural or locoregional anaesthesia or anaesthesia when enoxaparin sodium is<br>             used for curative treatment within the previous 24 hours<br>",NA,Measure of anti-Xa activity,NA,NA,NA,NA,NA,2020-07-22
0,1,NA,NA,The Effect of Inhalation of Thyme Oil with Standard Nationwide Medication on Respiratory Markers and Laboratory Findings in Patients with COVID-19,"Intervention 1: Intervention group: The intervention group in addition to receiving a standard nationwide medication [2 tablets of Hydroxychloroquine sulfate 200 mg as a single dose and 2 tablets of Kaletra(Lopinavir/Ritonavir) 200/200 mg every 12 hours], receives pure thyme oil every 8 hours (8 am, 4 pm, 12 pm) for 30 minutes through a nebulizer for 5 days. So that 4 drops of pure thyme oil with 10 cc of distilled water were prepared for each nebulization. Intervention 2: Control group: The control group in addition to receiving a standard nationwide medication [2 tablets of Hydroxychloroquine sulfate 200 mg as a single dose and 2 tablets of Kaletra(Lopinavir/Ritonavir) 200/200 mg every 12 hours], receives 10 cc of distilled water (placebo) every 8 hours (8 am, 4 pm, 12 pm) for 30 minutes through a nebulizer for 5 days.",http://en.irct.ir/trial/47572,Effect of of Inhalation of Thyme Oil in COVID-19,IRCT,IRCT20200426047212N1,2020-05-02,2020-05-04,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Allocation of samples to each of the intervention and control groups was performed by block random method using 4 blocks. Random chains and concealment codes were generated by the website ""www.sealedenvelope.com"". To hide the random chain, the method of envelopes in non-transparent packages is also used, Blinding description: Thyme oil and placebo oil is imported in uniform bottles of the same color and is given to patients and clinical caregivers in envelopes A and B. Thyme oil does not have a special smell and using the allowed color, the placebo is the same color as the medicine. All research teams except the lead researcher and the treating physician will be blind, and the information will be given to the analyzer by the treating physician with a special code extracted from the table of random numbers.",2-3,48,Shooshtar University of Medical Sciences,Iran (Islamic Republic of),"COVID-19. <br>COVID-19, virus identified;U07.1",FALSE,Yes,2020-05-02,2020-05-04,18 May 2020,NA,20200502,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,no limit,Both,Ali Hatami,NA,"Shahid Rajaei Ave., Al-Hadi Hospital, Education, Research, Cultural and Student Department of Shushtar Faculty of Medical Sciences",hatami_a@shoushtarums.ac.ir,+98 61 3622 8926,Shooshtar University of Medical Sciences,Inclusion criteria: Age over 18 years<br>Mild to moderate disease<br>Positive polymerase chain reaction (PCR) test<br>Lung involvement based on CT scan<br>Hospitalization,"Exclusion criteria: Patient death<br>Sensitivity to inhalation of the drug<br>Intolerance of nebulizer<br>Physician's diagnosis of not participating in the study<br>Pregnancy and lactation<br>Use of angiotensin-converting enzyme inhibitor<br>Severe renal, hepatic, respiratory and cardiovascular failure<br>Taking cytotoxic or corticosteroid drugs<br>Transfer to another hospital","Percentage of oxygen saturation. Timepoint: Before the start of the intervention, 5 consecutive days during the intervention and one day after the intervention. Method of measurement: Pulse oximeter.;Respiratory rate. Timepoint: Before the start of the intervention, 5 consecutive days during the intervention and one day after the intervention. Method of measurement: Count the respiratory rate per minute.",NA,NA,NA,NA,NA,2020-05-02
0,1,NA,NA,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial,Drug: Convalescent Plasma Transfusion;Other: Supportive Care;Drug: Random Donor Plasma,https://clinicaltrials.gov/show/NCT04346446,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,CT.gov,NCT04346446,2020-04-14,2020-04-20,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,29,"Institute of Liver and Biliary Sciences, India",India,COVID,TRUE,Yes,14/04/2020,"April 20, 2020",25 June 2020,NA,20200414,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,Yes,18 Years,N/A,All,NA,NA,NA,NA,NA,NA,"<br>        Inclusion Criteria:<br><br>        -<br><br>        Recipient:<br><br>        Severe COVID -19 infections defined as WHO Interim Guidance and the Guideline of Diagnosis<br>        and Treatment of COVID-19 of National Health Commission of China (version 5.0) with<br>        confirmation by real-time RT-PCR assay with severe disease i.e. meeting any 2 of the<br>        following criteria-<br><br>          1. Respiratory distress, RR =30 beats/min<br><br>          2. Oxygen saturation level less than 93% in resting state<br><br>          3. Partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) = 300 mmHg.<br><br>          4. Lung infiltrates > 50% within 24 to 48 hours<br><br>          5. Very sick (on ventilator) and patients with co-morbidities such as patients with known<br>             co-morbid diseases (COPD, CAD, CLD, CKD, cardiopulmonary disease-structural or<br>             valvular heart disease)<br><br>          6. Patient presenting with multi organ failure or requiring mechanical ventilation.<br><br>        Donor:<br><br>          -  Known case of recovered COVID-19 Infection, and<br><br>          -  Complete resolution of symptoms at least 28 days prior to donation or Complete<br>             resolution of symptoms at least 14 days prior to donation and negative results for<br>             COVID-19 either from one or more nasopharyngeal swab specimens or by a molecular<br>             diagnostic test from the blood, And Negative RT-PCR for COVID-19 on two sequential<br>             paired nasopharyngeal and throat specimens > 24 hrs apart (WHO-CDC guideline).<br><br>          -  Donor Plasma after 2 negative tests and 2 weeks of remaining asymptomatic, without<br>             antibody titre & presence of IgG/IgM antibodies to COVID-19 by serological as per<br>             manufacturers instructions. Donors negative for these will be deferred).<br><br>          -  Fulfill all criteria of donor eligibility for donor Plasmapheresis under the Drugs &<br>             Cosmetics Act and Rules 1945, amended 11.03.2020.<br><br>        Exclusion Criteria:<br><br>        - Recipient<br><br>          -  Patients with age less than 18 years.<br><br>          -  Pregnancy<br><br>          -  Individual with HIV and Hepatitis<br><br>          -  Morbid Obesity BMI>35 kg/m2<br><br>          -  Extremely moribund patients with an expected life expectancy of less than 24 hours.<br><br>          -  Failure to give informed consent from the patient or family members.<br><br>          -  Hemodynamic instability requiring vasopressors.<br><br>          -  Previous allergic history to plasma.<br><br>        Donor:<br><br>          -  Donors age < 18 & =60 years old<br><br>          -  Do not fulfil all criteria of donor eligibility for donor Plasmapheresis under the<br>             Drugs & Cosmetics Act and Rules 1945, amended 11.03.2020.<br><br>          -  Females who have been pregnant and previously transfused donors (to prevent TRALI).<br><br>          -  Donors who have taken steroids during treatment for COVID-19.<br>",NA,Proportion of patients remaining free of mechanical ventilation in both groups,NA,NA,NA,parent,NA,2020-04-14
0,1,NA,NA,"Comparison of the effectiveness of omega-3 and Hydroxychloroquine on Inflammatory factors, liver enzymes and clinical symptoms in diabetic COVID-19 patients",Intervention 1: Intervention group: 3 capsules containing 2010 mg EPA and DHA + 2 capsules containing 400 mg Hydroxychloroquine. Intervention 2: Control group: 2 capsules containing 400 mg Hydroxychloroquine.,http://en.irct.ir/trial/48045,Effect of omega-3 on diabetic patients with Covid-19,IRCT,IRCT20200511047399N1,2020-07-23,2020-02-20,FALSE,interventional,"Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Stratified Randomization method was used to control gender and BMI variables. BMI is considered normal (BMI= 18.5- 24.9) and abnormal (BMI= 25) and gender is considered as male and female, and thus four lists including women with normal BMI, women with abnormal BMI, men with normal BMI and men with abnormal BMI were considered. Patients were then divided into 2 groups by Permuted Block Randomization. In each separate list, the two-block modes (AB, BA) will be randomly assigned to each treatment order using a random number table. In each list, the order of treatment is determined and therefore, using the double blocks defined according to the random table, patients are placed in equal numbers in each group, Blinding description: the current study is a single-blinded clinical trial, in which the outcome assessor is not aware of each participant",3,30,Tehran University of Medical Sciences,Iran (Islamic Republic of),"Covid-19. <br>COVID-19, virus not identified;U07.2",FALSE,No,2020-07-23,2020-02-20,17 August 2020,NA,20200723,12/3/2020 5:31:55 PM,IRCT,Not Recruiting,No,18 years,no limit,Both,Mina Abdolahi,NA,"Amir-Alam hospital, Saadi St., Darvazeh Dolat STN., Enghelab St",abdolahimina.n@gmail.com,+98 21 6634 3352,Tehran University of Medical Sciences,Inclusion criteria: Body mass index equal to or more than 18.5<br>age equal to or more than 18<br>Diabetic patients diagnosed with covid-19 according to physician diagnosis  <br>Not consuming any particular diet or supplement as well as not doing any particular physical activity<br>Willingness to participate in the study,"Exclusion criteria: Having a history or current diagnosis of inflammatory disorders including liver, kidney or thyroid abnormalities, pancreatitis, any malignancy or other conditions that impact inflammatory status<br>Patients who had regularly received omega-3 supplements during 3 months before our trial<br>Pregnancy<br>Lactating<br>Menopause<br>Patients with history of smoking (at-least 5 cigarette per day) or alcohol intake during 6 months before our trial<br>any abnormality in PTT, PT or INR tests","Erythrocyte sedimentation rate (ESR). Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Automated erythrocyte sedimentation rate analyzer (ELECTA LAB S.r.l, Via Balzella, Italy).;C-reactive protein. Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Immunoturbidimetric method (Pars Azmun, Iran).;Fatigue. Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Self-reported questionnaire with sores ranging from 1 until 10.;Body pain. Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Self-reported questionnaire with sores ranging from 1 until 10.;Appetite. Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Self-reported questionnaire with sores ranging from 1 until 10.;Olfactory. Timepoint: In the baseline of the study and after 2 weeks supplementation with omega-3. Method of measurement: Self-reported questionnaire with sores ranging from 1 until 10.",NA,NA,NA,NA,NA,2020-07-23
0,1,NA,NA,"A double blind randomized controlled trial to assess safety and efficacy of Cap. IP in COVID-19 positive patients with mild to moderate severity for early recovery, in restoring respiratory health and in improvement in innate immunity",Intervention1: Cap. IP: Ayurvedic formulation to be taken twice daily in addition to standard of care<br>Control Intervention1: Placebo: Capsule to be taken twice daily in addition to standard of care<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45007,Safety and efficacy of Ayurvedic Capsule in mild to moderate COVID-19 infection.,CTRI,CTRI/2020/07/026570,2020-07-14,2020-07-15,FALSE,Interventional,"Randomized, Parallel Group Trial
  Method of generating randomization sequence:Random Number Table  Method of allocation concealment:Centralized  Blinding and masking:Participant and Investigator Blinded",N/A,60,AMAI Charitable Trust Pune,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,14-07-2020,15-07-2020,2 December 2020,NA,20200714,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Hrishikesh Rangnekar,NA,"D 204, Sun Planet, Sun city, Anand Nagar,",sureshpatankar51@gmail.com,NA,Quest Clinical Services,"Inclusion criteria: 1.Age  > 18 years <br/ ><br>2.All sexes  <br/ ><br>3.Case definitions for inclusion in the study will include mild to moderately severe cases as defined in the Guidance on appropriate treatment of suspect/confirmed case of COVI19 issued by Ministry of Health and Family Welfare, Govt of India on 07 Apr 2020. <br/ ><br>Mild: Cases presenting with fever and/or upper respiratory tract illness (Influenza like Illness, ILI); Moderate: Pneumonia with no signs of severe disease (Respiratory Rate 15 to 30/minute, SpO2 90%-94%). OR <br/ ><br>4.Laboratory confirmed SARS CoV-2 infection within last 10 days or SARS CoV-2 test result pending with a high clinical suspicion as defined by: Cough of more than 10 days duration OR <br/ ><br>5.Bilateral pulmonary infiltrates on chest X Ray / CT scan or new hypoxaemia defined as SpO2  <94% on room air, where no alternative explanation for respiratory symptoms can be given <br/ ><br>",Exclusion criteria: 1.Pregnant or lactating women <br/ ><br>2.Symptoms of acute respiratory tract infection for more than seven days  <br/ ><br>3.More than 48 hours have elapsed between meeting inclusion criteria and enrolment <br/ ><br>4.Subject is also a participant of any other clinical trial <br/ ><br>5.Serious / long-standing co-morbid conditions <br/ ><br>,Efficacy of Cap. IP (500 mg) in boosting innate immunity of patients with COVID-19 infection in one months duration.Timepoint: 1 month,NA,NA,NA,NA,NA,2020-07-14
0,1,NA,NA,A Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute Hypoxemia,Drug: Sargramostim;Drug: Standard of care,https://clinicaltrials.gov/show/NCT04411680,Study of Sargramostim in Patients With COVID-19,CT.gov,NCT04411680,2020-05-29,2020-08-18,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,60,"Partner Therapeutics, Inc.",United States,COVID-19;Sars-CoV2,FALSE,Yes,29/05/2020,"August 18, 2020",30 November 2020,iLeukPulm,20200529,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,NA,"Fiona Garner, PhD",NA,ileukpulmstudy@partnertx.com,(781)819-4949,NA,"<br>        Inclusion Criteria:<br><br>          -  Patients aged = 18 years<br><br>          -  Test positive for SARS-CoV-2 virus by PCR<br><br>          -  Admitted to hospital<br><br>          -  Presence of acute hypoxemia defined as (either or both)<br><br>               -  saturation below 93% on minimal (= 2 L/min) oxygen supplementation<br><br>               -  PaO2/FiO2 below 350<br><br>        Exclusion Criteria:<br><br>          -  Intubated and supported by mechanical ventilation<br><br>          -  Intractable metabolic acidosis<br><br>          -  Cardiogenic pulmonary edema<br><br>          -  Hypotension requiring use of vasopressors<br><br>          -  Hyperferritinemia (serum ferritin =2,000 mcg/L)<br><br>          -  White blood cell count > 50,000/mm3<br><br>          -  Participation in another interventional clinical trial for COVID-19 therapy<br><br>          -  Highly immunosuppressive therapy or anti-cancer combination chemotherapy within 24<br>             hours prior to first dose of sargramostim<br><br>          -  Known or suspected intolerance or hypersensitivity to sargramostim, or any component<br>             of the product<br><br>          -  Previous experience of severe and unexplained side effects during aerosol delivery of<br>             any kind of medical product<br><br>          -  Presence of any preexisting illness that, in the opinion of the Investigator, would<br>             place the patient at an unreasonably increased risk through participation in this<br>             study<br><br>          -  Pregnant or breastfeeding females<br>",NA,Change in oxygenation parameter of P(A-a)O2 gradient by Day 6;Percent of patients who have been intubated by Day 14,NA,NA,NA,NA,NA,2020-05-29
1,0,NA,NA,"Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study",Dietary Supplement: Nigella sativa,https://clinicaltrials.gov/show/NCT04401202,Nigella Sativa in COVID-19,CT.gov,NCT04401202,2020-05-21,2020-05-21,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,200,King Abdulaziz University,Saudi Arabia,COVID-19;SARS-CoV-2,FALSE,Yes,21/05/2020,"May 21, 2020",4 June 2020,NA,20200521,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,80 Years,All,;,"Abdulrahman Koshak, Dr;Abdulrahman Koshak, Dr",NA,aekoshak@kau.edu.sa;aekoshak@kau.edu.sa,6400000;6400000,NA,"<br>        Inclusion Criteria:<br><br>          -  Patients with COVID19 upper respiratory tract infection with no evidence of pneumonia<br><br>          -  Adult (18 Years and above)<br><br>          -  Written informed consent prior to initiation of any study procedures by the patient<br>             (or legally authorized representative).<br><br>          -  Understands and agrees to comply with planned study procedures.<br><br>          -  Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by<br>             polymerase chain reaction (PCR) available at KAUH.<br><br>        Exclusion Criteria:<br><br>          -  Patients with pneumonia or severe illness requiring admission to ICU.<br><br>          -  Severe chronic kidney disease (i.e. estimated glomerular filtration rate (eGFR) < 30)<br>             or end stage renal disease requiring dialysis<br><br>          -  Sever chronic liver disease (Alanine transaminase/aspartate transaminase (ALT/AST) > 5<br>             times the upper limit of normal).<br><br>          -  Pregnancy or breast feeding.<br><br>          -  Anticipated transfer to another hospital which is not a study site within 72 hours.<br><br>          -  Allergy to any study medication.<br>",NA,Proportion of patients who are clinically recovered,NA,NA,NA,NA,NA,2020-05-21
0,1,NA,NA,Identification of Predictive Immune Biomarkers Based on the Understanding of COVID-19 Pathogenesis to Influence Therapeutic Management,Biological: Blood collection on admission and longitudinally;Biological: Blood collection on their first consultation and 10 to 14 days later,https://clinicaltrials.gov/show/NCT04385108,Predictive Immune Biomarkers for COVID-19 Pathogenesis,CT.gov,NCT04385108,2020-05-05,2020-03-04,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,N/A,170,"University Hospital, Toulouse",France,COVID-19,FALSE,Yes,05/05/2020,"March 4, 2020",10 August 2020,COVIDBioToul,20200505,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ;,"Guillaume MARTIN-BLONDEL, MD PhD;Guillaume MARTIN-BLONDEL, MD PhD;Guillaume MARTIN-BLONDEL, MD PhD",NA,;martin-blondel.g@chu-toulouse.fr;martin-blondel.g@chu-toulouse.fr,;561779699;561779699,"University Hospital, Toulouse;","<br>        Inclusion Criteria:<br><br>        For COVID-19 hospitalized patients<br><br>          -  Polymerase chain reaction (PCR) proven SARS-CoV-2 infection<br><br>          -  Participation to Toulouse clinical cohort<br><br>          -  Having signed consent for inclusion in the Toulouse biobanks For COVID-19 healthcare<br>             workers attending dedicated clinics<br><br>          -  PCR proven SARS-CoV-2 infection<br><br>          -  Having signed consent for inclusion in the Toulouse biobanks<br><br>        Exclusion Criteria:<br><br>          -  Pregnancy or breastfeeding<br><br>          -  Participation in another interventional clinical study involving exploratory treatment<br>             or blood sampling.<br>",NA,Immune signature;Dosage of cytokines and chemokines in plasma samples,NA,NA,NA,NA,NA,2020-05-05
0,1,NA,NA,"Evaluation of the effect of Iranian medicine product, Algro, on the symptoms of patients with covid-19 (Coronavirus 19 disease)","Intervention 1: Intervention group: The medicinal product includes a capsule composed of two herbs(salix ,lambs quarter). The amount of each of these substances in the capsule is 250 mg. The dosage of the product is three capsules a day, which is half an hour before each meal. This product is prepared by Armaghan Sabz Araz Teb Pharmaceutical Company.In this group, common medical drug is also consumed according to the latest protocol of the Ministry of Health. Intervention 2: Control group: Patient in control group use  common medicine based on the latest protocol of the Ministry of Health and placebo.",http://en.irct.ir/trial/47019,"Evaluation of the effect of Iranian medicine product, Algro, on patients with coronavirus 19",IRCT,IRCT20160131026298N3,2020-04-30,2020-05-04,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method will be  blocked randomization (Quaternary random blocks). Randomization units are individuals. Eighty outpatients referred to the hospital emergency department are randomly assigned to one of the two intervention and control groups. This study is a double-blind method and patients in the intervention group will receive the intervention drug in addition to the routine treatment, but in control group, they will receive the placebo in addition to the routine treatment, Blinding description: Blinding will be performed using a placebo in the control group.",2-3,80,Bagheiat-allah University of Medical Sciences,Iran (Islamic Republic of),"COVID-19. <br>U07.2 COVID-19, virus not identified, COVID-19;U07.2",FALSE,Yes,2020-04-30,2020-05-04,30 November 2020,NA,20200430,12/3/2020 5:31:55 PM,IRCT,Not Recruiting,No,18 years,no limit,Both,Ahmad Reza Sharifi Olounabadi,NA,"Vice-Chancellor for Research and Technology, Third Floor, Baqiyatallah University, Sheikh Bahaei St, Mulla Sadra St, Vanak Square",a-sharifi@bmsu.ac.ir,+98 21 8755 5250,Bagheiat-allah University of Medical Sciences,Inclusion criteria: Male or female patients 18 years old and older with COVID-19<br>positive coronavirus 19 PCR<br>Ground glass view at low-dose CT scan<br>Arterial oxygen saturation less than 93%<br>Consciously completed consent form completed by the patient or the patient's supervisor,Exclusion criteria: History of pulmonary malignancy<br>History of asthma or COPD<br>History of Disabling disease or malignancy<br>Liver or kidney disorders,Measurement of cough severity. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Standard cough questionnaire.;Severity of shortness of breath. Timepoint: Day 1 before and at the end of treatment. Method of measurement: Shortness Of Breath With Daily Activity (SOBDA) Questionnaire.;Lung radiologic changes. Timepoint: At beginning and end of the study. Method of measurement: Chest CT scan.,NA,NA,NA,NA,NA,2020-04-30
0,1,NA,NA,Cohort of Patients Infected With SARS-CoV2 or Suspected of Being (COVID-19 in Ile-de-France),Other: blood samples;Other: feces samples (COVI-BIOME ancillary study);Other: sweat samples (COVIDOG ancillary study),https://clinicaltrials.gov/show/NCT04352348,Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,CT.gov,NCT04352348,2020-03-31,2020-03-31,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).,N/A,2000,Assistance Publique - Hôpitaux de Paris,France,COVID-19,FALSE,Yes,31/03/2020,"March 31, 2020",31 August 2020,COVIDeF,20200331,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,; ;,"Pierre HAUSFATER, MD;Pierre HAUSFATER, MD;Pierre Hausfater, MD",NA,;pierre.hausfater@aphp.fr;pierre.hausfater@aphp.fr,;+331 42 17 72 40;+331 42 17 72 40,GH Pitié Salpêtrière - Charles Foix;,"<br>        Inclusion Criteria:<br><br>          -  Age = 18<br><br>          -  Patient admitted in an emergency unit or hospitalized, infected with SARS-CoV2 or<br>             suspected of being<br><br>          -  Written informed consent or emergency procedure<br><br>          -  Affiliated to health insurance system<br><br>        Exclusion Criteria:<br><br>          -  Refusal of participation<br><br>          -  Patient under justice protection measure except guardianship and trusteeship<br>",NA,Identification of prognostic factors for progression to a severe form of COVID-19 infection,NA,NA,NA,NA,NA,2020-03-31
1,0,NA,NA,Evaluating the effect of Melatonin in prognosis and clinical improvement in patients with COVID-19: A Randomized Clinical Trial,"Intervention 1: Intervention group: Melatonin supplement at a dose of 18 mg twice a day for 7 days and orally, with standard treatment. Intervention 2: Control group: They will receive the national standard treatment of Covid-19.",http://en.irct.ir/trial/51687,Effect of Melatonin in treatment of COVID-19,IRCT,IRCT20200426047206N4,2020-11-01,2020-10-22,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: For randomization, we will use the method of Balanced Block Randomization (block size: 4). For this purpose, we prepare four sheets of paper. On the two sheets, we write the I meaning ""Intervention"" and on the other two sheets we write the P meaning ""Placebo"". Mix the sheets together and place them in the desk drawer. When referring to any of the eligible patients, one of the sheets was randomly taken out, and based on this sheet, I or P was assigned to one of the two groups of intervention (melatonin recipient) or comparison (placebo recipient). They will be. Extracted tabs will not be returned to the drawer until all four tabs have been extracted. After randomly pulling out all four sheets, all the sheets are returned to the drawer and the above procedure will be continued for the next four patients until the desired sample size (60 patients) i",3,60,Hamedan University of Medical Sciences,Iran (Islamic Republic of),Covid-19. <br>covid-19;U07.1,FALSE,No,2020-11-01,2020-10-22,30 November 2020,NA,20201101,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,75 years,Both,Salman Khazaei,NA,"Fahmideh street,  Pajoohesh Blvd, Hamadan City",salman.khazaei61@gmail.com,+98 81 3838 0548,Hamedan University of Medical Sciences,Inclusion criteria: Age between 18-75 year<br>Hospitalized in ward<br>Confirmed diagnosis with PCR<br>Elapsed less than 48 hour from symptom onset<br>Not pregnant or breastfeeding<br>Do not have moderate to severe liver and renal problems.<br>Not treated with immunosuppressive drugs during the last 3 months,Exclusion criteria: Drug intolerance,Need to oxygen therapy rate. Timepoint: During treatment. Method of measurement: view patients medical file.;Rate of sleep and depression. Timepoint: Hospital Anxiety and Depression Questionnaire. Method of measurement: Score.;The amount of hospitalization in the intensive care unit during 28 days. Timepoint: Day 28 after treatment. Method of measurement: view patients medical file.,NA,NA,NA,NA,NA,2020-11-01
1,0,NA,NA,Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19,"Intervention 1: Intervention group: People in the intervention group will receive  nanocurcumin supplement at a dose of 160 mg per day for 6 days. Curcumin is a natural polyphenolic antioxidant responsible for the turmeric yellow color. Nanocurcumin supplements are produced in the form of 40 mg capsules by Exir Nano Sina Company, and patients will receive 4 supplements orally (every 12 hours 2 capsules) for 6 days in addition to the routine treatment,. Intervention 2: Control group: People in the control group are given placebo capsules that are completely similar to nanocurcumin supplements in terms of shape and color and are asked to take 4 placebo capsules daily (every 12 hours 2 capsules) for 6 days.",http://en.irct.ir/trial/51310,Assessment of the effect of nanocurcumin supplement in patients with COVID-19,IRCT,IRCT20131125015536N13,2020-10-03,2020-05-21,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomization is done by permuted block method. First, all possible quadruple blocks are considered and a number is assigned to each of them. Then, using a table of random numbers and the number assigned to each block, a random sequence is determined. Eligible individuals included in the study are placed in the intervention or control group according to the sequence determined based on randomization, Blinding description: In order to keeping patients, clinical caregivers, and the outcome assessor blind, the placebo will be prepared of the same color and shape as the supplement so that no one could distinguish the supplement from the placebo. The main researcher, who is not in direct contact with patients, is the only person who is not blind and pours supplements and placebos into exactly the same cans, specifies the cans with a three-digit numbe",N/A,48,Tehran University of Medical Sciences,Iran (Islamic Republic of);Iran (Islamic Republic of),"COVID-19. <br>Coronavirus infection, unspecified;U07.1",FALSE,No,2020-10-03,2020-05-21,6 October 2020,NA,20201003,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,30 years,70 years,Both,Mohammad Javad Hossein Zadeh,NA,"School of Nutritional Sciences and Dietetics, No. 44, Hodjat doost Alley, Naderi St., Keshavarz Blvd.",mhosseinzadeh@tums.ac.ir,+98 21 8895 5975,Tehran University of Medical Sciences,Inclusion criteria: Confirmation of Covid-19 by positive PCR test or lung scan<br>Admission to hospital Corona wards other than ICU<br>Filling out the informed consent form by the patient or the patient's first-degree relatives,Exclusion criteria: Chemotherapy<br>People living with HIV<br>History of heart attack and stroke in the last 3 months<br>History of CABG<br>Dialysis patients<br>Transplantation of body organs<br>Pregnancy and lactation<br>People with BMI above 40<br>Known food allergies<br>Having any liver failure<br>Malignancies<br>Uncontrolled Diabetes (A1c>7.5),Hs-CRP. Timepoint: Before and after 6 days of supplementation. Method of measurement: ELISA.;Percentage of recovery. Timepoint: Before and after 6 days of supplementation. Method of measurement: CT scan of the lungs.,NA,NA,NA,NA,NA,2020-10-03
0,1,NA,NA,Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19),Experimental Group:Xiaotan Sanjiefang granule;Control Group:placebo (contain 5% test drug);,http://www.chictr.org.cn/showproj.aspx?proj=51940,Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19),ChiCTR,ChiCTR2000031672,2020-04-06,2020-04-01,FALSE,Interventional study,Parallel,0,Experimental Group:75;Control Group:75;,Beijing University of Chinese Medicine,China,Novel Coronavirus Pneumonia (COVID-19),FALSE,No,2020-04-06,2020-04-01,14 September 2020,NA,20200406,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,18,70,Both,Yingshuai Li,NA,"11 Beisanhuan Road East, Chaoyang District, Beijing, China",liyingshuai2013@163.com,+86 13681410020,Beijing University of Chinese Medicine,"Inclusion criteria: 1. Meet the history of COVID-19 confirmed in accordance with the diagnosis and treatment plan of COVID-19(trial seventh edition);<br>2. Meet the discharge standards of COVID-19(trial seventh edition);<br>3. Meet the diagnosis standard of qi deficiency and phlegm stasis syndrome;<br>4. Patients aged 18-70 years old, 28 days after discharge, still have abnormal manifestations on lung CT;<br>5. Patients willing to sign informed consent.","Exclusion criteria: 1. Patients with primary and secondary cardiovascular, cerebrovascular, renal, endocrine, neurological and blood system diseases, tumors and tuberculosis;<br>2. Patients who have participated in or are participating in other clinical trials within one month;<br>3. Patients with mental disorders who can not express their feelings;<br>4. There are other situations that are not suitable to be included in the study.",Lung CT Score;,NA,NA,NA,NA,NA,2020-04-06
0,1,NA,NA,Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19),Drug: Oral-B Mouth Sore mouthwash;Drug: Crest Pro-Health Multi-Protection mouthwash;Drug: CloSYS mouthwash;Drug: Distilled water;Drug: Listerine Mouthwash Product,https://clinicaltrials.gov/show/NCT04409873,Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),CT.gov,NCT04409873,2020-05-28,2020-12-07,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Double (Participant, Outcomes Assessor).",Phase 2,150,"University of California, San Francisco",United States,COVID-19;SARS-CoV 2;Severe Acute Respiratory Syndrome Coronavirus 2;Virus Disease;Coronavirus Infections;Pharyngeal Diseases,FALSE,Yes,28/05/2020,"December 7, 2020",30 November 2020,AMPoL,20200528,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,; ;,"Stuart A Gansky, DrPH;Stuart A Gansky, DrPH;Stuart A Gansky, DrPH",NA,;stuart.gansky@ucsf.edu;stuart.gansky@ucsf.edu,;415-502-8094;415-502-8094,Professor and Lee Hysan Chair of Oral Epidemiology;,"<br>        Inclusion Criteria:<br><br>          -  Tested positive for COVID-19 in prior 7 days<br><br>          -  Ability to read and speak English or Spanish<br><br>          -  Ability to participate in the study for 4 weeks<br><br>          -  Ability to gargle<br><br>          -  Not having any condition that might worsen with gargling solutions<br><br>          -  Not having an allergy to a study mouthwash ingredient<br><br>          -  Not using another mouthwash/gargling solution<br><br>          -  Not taking antimicrobial medications (antibacterial, antiviral, antibiotics including<br>             off-label FDA-approved medications such as hydroxychloroquine)<br><br>          -  Anticipated ability to participate in the study for 4 weeks<br><br>          -  Have a cellphone and agree to receive text messages for reminders to use mouthwash<br>             during the day and for follow-up visits<br><br>        Exclusion Criteria:<br><br>          -  People who because of their symptoms intend to receive antiviral medications that<br>             could potentially affect viral load in their saliva samples<br><br>          -  Pregnant or lactating women due to potential aversions to mouthwash solution<br>             taste/smell.<br>",NA,Change in SARS-Cov-2 viral load,NA,NA,NA,NA,NA,2020-05-28
0,1,NA,NA,A Study on prophylactic interventions of Unani Medicine on high/moderate risk population of COVID 19,"Intervention1: Khameera Marwareed: 5g orally once daily in the morning for 14days<br>Intervention2: Tiryaq-e-Arba: 5gm orally with lukewarm water in the Morning for 14days<br>Intervention3: Unani Joshanda/decoction (Behidana (Cydonia oblonga) 3 gm, Unnab (Zizyphus jujube)<br>5 in number, Sapistan (Cordia myxa)9 in numbers: lukewarm decoction once<br>daily in the Evening for 14days<br><br>Intervention4: Conventional treatment being given in quarantine centers in Delhi: As per Centre/State Govt policy<br>Control Intervention1: Conventional treatment being given in quarantine centers in Delhi: As per Centre/State Govt policy<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44584,"A Study on Unani regimen 
for prevention of high/moderate risk population of COVID 19",CTRI,CTRI/2020/06/026227,2020-06-29,2020-07-07,FALSE,Interventional,"Non-randomized, Multiple Arm Trial
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable",Phase 3,60,Central Council for Research in Unani Medicine CCRUM New Delhi,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,29-06-2020,07-07-2020,2 December 2020,NA,20200629,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Pradeep Kumar,NA,"Room No. 516, Jawahar Lal Nehru Bhartiya Chikitsa Evam Homoeopathy Anusandhan Bhawan, 61-65, Institutional Area, Opp. D Block, Janakpuri",ccrum507@rediffmail.com,9213511298,CCRUM,Inclusion criteria: 1.Population as described as High/ Moderate Risk group  <br/ ><br>2.Individuals who are from the identified quarantine facility <br/ ><br>3.Subjects who are ready to provide written/digital informed consent and who are willing to participate and follow the protocol requirements of the clinical study,"Exclusion criteria: 1.Persons with severe primary respiratory disease or related complications that may be <br/ ><br>identified with COVID-19 <br/ ><br>2.Laboratory confirmed COVID-19 with or without symptoms <br/ ><br>3.Pregnant and lactating mothers and those who have a pregnancy plan. <br/ ><br>4.Persons with serious critical illness, or severe mental illnesses <br/ ><br>5.Individuals with clinical history of uncontrolled/ unstable co-morbidities <br/ ><br>6.Known Immuno-compromised individuals or those on immune-suppressantdrugs and steroids <br/ ><br>7.Subjects having a past history of allergy to any medicine that is a part of the Unani <br/ ><br>intervention.",Incidence of COVID-19 cases in control as well in interventional group <br/ ><br>Timepoint: 14 days,NA,27/07/2020,NA,NA,NA,2020-06-29
0,1,NA,NA,A prospective randomized controlled clinical trial to evaluate the efficacy and safety of Ayurvedic interventions in the management of COVID-19(Asymptomatic to moderate cases),"Intervention1: Ayush-64, Agasthya Haritaki, Anu taila Nasal drops: AYUSH-64 500 mg Tablets Oral<br>Twice a day 2 hrs after food<br>Lukewarm water for 10 days<br>Agasthya Haritaki Avleha 5 gm<br><br>Oral<br>Twice a day 2 hrs before food Lukewarm water for 10 days<br>Anu taila 2 drops<br>Oil Nasal instillation<br>Twice a day for 10 days<br>Intervention2: Broncho-T Granules: 50 ml<br>Decoction Oral Thrice a day 1 hrs before food Lukewarm water<br>for 10 days<br>Control Intervention1: Standard conventional treatment as per ICMR guidelines: Symptomatic care<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46229,To assess the clinical efficacy of Ayurvedic interventions in managing asymptomatic to mild cases of COVID-19,CTRI,CTRI/2020/08/027346,2020-08-24,2020-08-25,FALSE,Interventional,"Randomized, Parallel Group, Active Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Not Applicable",Phase 2/ Phase 3,60,Shri Dhanwantry ayurevdic college and hospital,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,24-08-2020,25-08-2020,2 December 2020,NA,20200824,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Shikha Chaudhary,NA,"Department of Research, room no 110, shri dhanwantry ayurvedic college and hospital 77 chandi path sector 46 B Chandigarh",drshikha08@icloud.com,9205109463,shri dhanwantry ayurvedic college and hospital,"Inclusion criteria: Asymptomatic to moderate cases registered in the Hospital, above 18 years of age of either gender, with COVID 2019 (Confirmed by Antigen test/ RT-PCR) quarantined at our hospital. <br/ ><br>2. Participants who can take medicines orally <br/ ><br>3. Patients willing to provide signed informed consent","Exclusion criteria: 1.	Patients suffering from severe COVID-19 Disease as judged by a physician <br/ ><br>2.	Chronic, Severe, Unstable, Uncontrolled co-existent medical illness such as Diabetes, Hypertension, Cardiac disorders, liver, kidney disorders and lung disorders or other disease of concern which may put the patient at increased risk during the study <br/ ><br>3.	Patients who are likely to worsen or planed ICU admission or ventilator support due to any reason <br/ ><br>4.	Pregnancy and lactation <br/ ><br>5.	Participation in a drug interventional clinical drug trial of any nature in the three month period preceding onset of COVID-19 <br/ ><br>6.	Participation in any other clinical trial of an experimental agent treatment for COVID-19 <br/ ><br>7.	 Patients on any kind of Ayurveda treatment or any other alternative and complementary medicinal systems such as Homeopathy, Unani, Siddha and in particular requiring oral therapy of any kind. <br/ ><br>8.	Physician decision that involvement in the study is not in the patientÂ´s best interest. <br/ ><br>",1.	Mean time for clinical recoveryTimepoint: 1.	5th and 10th day,NA,NA,NA,NA,NA,2020-08-24
0,1,NA,NA,"A Prospective ,randomized ,double blind,placebo controlled study to access effects of nano ozonized hydrogen peroxide nebulization on results of RTPCR for noval corona virus thus infectivity and clinical course among mild to moderate sick Covid 19 patients HOPE in Covid 19(Hydrogen Peroxide Inhalation).",Intervention1: Triozone: 1 ml of trio zone mixed with 4 ml of normal saline given 3 times a day from nasal route   . a cumulative 5ml  single dose is used for nebulisation by nasal route once a day  .<br>Control Intervention1: Placebo: 5ml of 0.9 % normal saline will be used as placebo given by nasal route . thrice  a day  at same doses of trial drug. Normal saline do not have any effects over virus replication and free of any side effects.<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46197,Study  to assess effects of nano ozonised hydrogen peroxide nebulisation on results of RT-PCR for novel corona Virus thus infectivity and clinical course among mild to moderate sick COVID-19 Patients,CTRI,CTRI/2020/08/027038,2020-08-07,2020-08-20,FALSE,Interventional,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:On-site computer system  Blinding and masking:Participant and Investigator Blinded",Phase 3,100,SN medical College,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,07-08-2020,20-08-2020,2 December 2020,NA,20200807,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,DrAshish Gautam,NA,Department of Medicine SN Medical College  Raja Mandi near Central library Agra-282003,ppagrawal120@gmail.com,9319250485,S N Medical College,Inclusion criteria: All newly diagnosed patients  <br/ ><br>Not requiring mechanical ventilation <br/ ><br>on oxygen therapy <br/ ><br>Tolerating hydrogen peroxide nebuliser <br/ ><br>Consenting patients <br/ ><br>On same treatment protocol,Exclusion criteria: Patients not giving consent <br/ ><br>Patient not tolerating nebulization,Proportion of patients who turned negative on RT-PCR for for nCOV for two consecutive days.Timepoint: 6 month,NA,NA,NA,NA,NA,2020-08-07
0,1,NA,NA,Evaluation of efficacy of Arogya Kashayam in Asymptomatic and Mild Symptomatic Positive Cases of Covid-19 -A Randomized  Control Study,Intervention1: Arogya Kashayam-20: Dose : 100 ml <br>Frequency: Twice a day (morning and evening)<br>Route: Oral.<br>Duration: 10 days.<br>Control Intervention1: Hydroxychloroquine (HCQ): Dose: First day - 800 mg<br>maintenance dose for next five days - 400 mg. <br>Frequency: Twice a day in divided dose.<br>Route : Oral.<br>Duration: 6 days.<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44542,Intervention of Ayurvedic Medicine (Arogya Kashayam) in Covid-19 positive cases (Asymptomatic and Mild Symptomatic),CTRI,CTRI/2020/06/026221,2020-06-29,2020-07-01,FALSE,Interventional,"Randomized, Parallel Group, Active Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Participant Blinded",Phase 2,100,Directorate of AYUSH Government of Madhya Pradesh,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,29-06-2020,01-07-2020,2 December 2020,NA,20200629,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Prof Umesh Shukla,NA,"Department of Panchkarma, Room No. 101, ""A"" Block, Academic wing, Pt Khushilal Sharma Government Ayurveda College and Institute Science Hills Dhanwantrari Marg Bhopal 462039",umeshayurvedabhopal@gmail.com,9425373046,Pt Khushilal Sharma Government Ayurveda College and Institute Bhopal,"Inclusion criteria: Asymptomatic and Mild cases of Covid-19 <br/ ><br> <br/ ><br>Aged between 16-60 years without any discrimination of gender, caste and religion <br/ ><br> <br/ ><br>Participants able to give Informed consent and follow the instructions <br/ ><br>",Exclusion criteria: Severely symptomatic cases of Covid-19 (SaO2  <90%) <br/ ><br> <br/ ><br>Participants with Acute Respiratory Distress Syndrome (ARDS) <br/ ><br> <br/ ><br>Life expectancy less than 1 year due to other co-morbid conditions <br/ ><br>,"Check the progression of the diseaseTimepoint: Base line, 3 days, 7 days",NA,10/08/2020,NA,NA,NA,2020-06-29
0,1,NA,NA,"Full versus prophylactic heparinization for the treatment of severe forms of SARS-Covid-19: clinical, randomized, open and controlled study - HeSAcovid trial","Patients will be randomized in a 1: 1 ratio between two groups through a digital application.<br>Group 1) Full heparinization with enoxaparin: Full heparinization will be performed with enoxaparin adjusted for creatinine clerance according to the scheme below): 10 patients<br>Creatinine clearance <75 years> 75 years<br>> 50 ml / min 1 mg / Kg SC BID 0.75 mg / Kg SC BID<br>30-50 ml / min 0.75 mg / Kg BID 1 mg / Kg SC 1x<br>10-30 ml / min 1 mg / kg SC1x 0.75 mg / kg 1x<br><10 ml / h Will not be included Will not be included<br><br>As renal function can change during the study, we consider daily creatinine dosage necessary and the adjustment of the dose of enoxaparin should be performed daily according to the evolution of renal function. Duration of heparinization: 96 hours. Enoxaparin may be extended up to 7-10 days at the discretion of the medical team for those patients who show significant clinical improvement. Enoxaparin may be suspended at any time if any major or minor bleeding is observed according to the safety criteria included in this study or platelet count below 30,000 mm3. If, during the course, renal function worsens with creatine clearance below 10 ml / min, he should receive unfractionated heparin adjusted by APTT aiming at a ratio between 1.5 and 2.0.<br><br>Group 2) Prophylactic heparinization: 10 patients<br><br>The control group will receive prophylactic heparin with unfractionated heparin SC at a dose of 5000 IU 8/8 h or enoxaparin 40 mg SC 1 x day. In obese patients (weight> 120 kg), the dose in UFH SC may be increased to 7500 IU SC 8/8 hs and the dose of enoxaparin may be increased to 40 mg SC 12/12 h<br><br><br>Note: The full UFH arm was abandoned due to difficulties in adjusting the heparin dose in these patients requiring multiple test collection;Drug;Anticoagulants",http://www.ensaiosclinicos.gov.br/rg/RBR-949z6v/,Full versus prophylactic anticoagulation for the treatment of severe forms of Covid-19:,RBR,RBR-949z6v,2020-05-06,2020-05-30,FALSE,Intervention,"Clinical trial of treatment, randomized-controlled, parallel, open, with two arms: first group will use full heparinization with enoxaparin corrected for creatinine clerance, compared with prophylactic heparinization through unfractionated heparin 5000 IU SC 8/8 hs ( 7500 IU 8/8 h in patients> 120Kg) or enoxaparin 40 mg SC 1 x day (40 mg BID if weight> 120 Kg) in patients with confirmed SARS-CoV-2 infection through RT-PCR and with severe clinical presentation respiratory failure requiring mechanical ventilation or refractory to oxygen therapy (maintenance of respiratory rate> 24 ipm and saturation <90% with oxygen catheter at 4 liters / min). The following tests will be collected: blood gas, lactate, D-dimer, PCR, biomarkers of endothelial glycocalyx lesion (syndecan-1, hyalurane, thrombomodulin, heparan sulfate, soluble CD44, chondroitin sulfate) at the time of inclusion (D0) and after 96 hours of heparinization (D4). The primary outcomes are: comparison between before and after",2,30,"Faculdade de Medicina de Ribeirão Preto - Ribeirão Preto, SP, Brazil",Brazil,"covid-19
acute respiratory distress syndrome <br>Coronavirus as the cause of diseases classified to other chapters ;A00-B99;Coronavirus as the cause of diseases classified to other chapters",FALSE,Yes,06/05/2020,30/05/2020,4 November 2020,NA,20200506,12/3/2020 5:31:55 PM,REBEC,Recruiting,No,18Y,85,-,Carlos,Miranda,"Rua Bernardino de Campos, 100",chmiranda@fmrp.usp.br,+55-16-32371470,Faculdade de Medicina de Ribeirão Preto,"Inclusion criteria: Age above or equal to 18 years; SARS-covid-19 infection confirmed through RT-PCR; Severe forms confirmed by the presence of ARDS according to the Berlin classification ( bilateral infiltrate on chest X-ray, arterial hypoxemia with a PaO2 / FIO2 ratio <300, absence of structural heart disease or evidence of insufficiency acute cardiac arrest; Presence of severe clinical presentation with respiratory failure requiring orotracheal intubation or mechanical ventilation or maintenance of RF> 24 ipm and saturation <90% after the administration of supplemental oxygen through a nasal catheter at 4 liters / min; Dosage of D-dimer greater than and equal to 0.5 pg / ml; Presence of prothrombin time (TP / INR) <1.5 and APTT (activated partial thromboplastin time (APTT) <1.5; Platelet count greater than 100,000 / mm3","Exclusion criteria: Age over 85 years; creatinine clearance <10 ml / min; severe circulatory shock with a dose of norepinephrine greater than 1.0 pg / Kg / min; Chronic renal patients on hemodialysis; chronic Child B and C liver disease; advanced diseases (active neoplasia, heart failure functional class III and IV, COPD in chronic use of oxygen with more than 2 exacerbations in the last year, advanced dementia, bedridden patient with significant sequelae of stroke or traumatic brain injury; cardiorespiratory arrest; pregnant women; recent major surgery in the last 3 weeks; recent stroke in the last 3 months; presence of active bleeding; presence of blood dyscrasia such as: hemophilia, Von Willebrand factor deficiency, etc.; participation in another clinical investigation with associated intervention; formal indication for oral anticoagulation for other reasons such as: pulmonary embolism, acute coronary syndrome, etc.","Evaluation of gas exchange between D0 / D4 /D7 /D14 evaluated through the PO2 / FIO2 ratio; days without mechanical ventilation (within 28 days of follow-up, how many days were out of mechanical ventilation, if the patient dies before 28 days of follow-up, it is considered that he did not stay any day out of mechanical ventilation)",NA,NA,NA,NA,NA,2020-05-06
0,1,NA,NA,"Role of Dantabija, Haridra and Zingiber officinale in halting progression and reducing duration of mild to moderate COVID-19 disease","Intervention1: Dantabija, Haridra and Zingiber officinale Lozenges: Intervention group will recieve standard treatment plus chewable tablets containing ginger, turmeric and pomegranate extracts (Dantabija 20mg + Haridra 50mg + Zingiber officinale 5mg) in a dose of 3  tablets/day for 10 days.<br>This drug is already available in market.<br>Control Intervention1: Paracetamol, Zinc and Vitamin C, Azithromycin, Low molecular weight heparin, Hydroxychloquine, Methyl Prednisolone: For  mild cases:-<br>Antipyretic (Paracetamol) for fever and pain if complain of fever.<br>Adequate nutrition and appropriate rehydration. <br>Supplements like zinc and vitamin C, and <br>Tab Azithromycin 500mg OD, if there is symptoms of upper respiratory tract infection. <br>For moderate disease:- All above and<br>Oxygen Support: <br>All patients should have daily 12-lead ECG <br>Follow CRP, & Ferritin every 48-72 hourly, CBC with differential count, Absolute Lymphocyte count, KFT/LFT daily <br>Tab. Hydroxychloroquine (400mg) BD on 1st day followed by 200mg 1 BD for 4 days. (after ECG Assessment) <br>IV methylprednisolone 0.5 to 1 mg/kg for 3 days (preferably within 48 hours of admission or if oxygen requirement is increasing and if inflammatory markers are increased) <br>Anticoagulation <br>Prophylactic dose of UFH or LMWH (e.g., enoxaparin 40 mg per day SC)<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48233,"Can combination of Haldi, Pomegranate and Zinger extract tablets help in reducing duration of hospital stay of mild to moderate COVID-19 patients.",CTRI,CTRI/2020/11/029038,2020-11-11,2020-10-19,FALSE,Interventional,"Randomized, Parallel Group, Active Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Not Applicable",Phase 3,100,Alchem Phytoceuticals,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,11-11-2020,19-10-2020,2 December 2020,NA,20201111,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Yogesh Kumar,NA,"Department of Physiology
All India Institute of Medical Sciences Patna, Phulwarisharif, Patna",dryogeshk@aiimspatna.org,7759835573,AIIMS Patna,Inclusion criteria: a)COVID-19 RT-PCR test/ COVID-19 antigen test/COVID-19 TRUNAT test Positive <br/ ><br>b) All Males and Females between 5 to 70 years. <br/ ><br>c) Having history of dry cough/fever/malaise/rhinorrhea/New loss of taste and smell/Gastrointestinal upset. <br/ ><br>d) Patients who can take medicines orally. <br/ ><br>e) No Oxygen requirement/ Oxygen requirement of  less than 5L/minute.,Exclusion criteria: a) Oxygen requirement of  more than 5L/minute. <br/ ><br>b) Patients who are on Ventilatory support. <br/ ><br>c) Who cannot take medicines by oral route? <br/ ><br>d) Patients who are on  dialysis. <br/ ><br>e) Age less than five years and more than 70 years. <br/ ><br>f) Patients taking any other Ayurvedic supplement.,"To Evaluate efficacy of combination of Dantabija 20mg, Haridra 50mg and  Zingiber officinale 5mg in controlling COVID-19 Disease  <br/ ><br>We will measure following parameters <br/ ><br>1)COVID-19 RT PCR test <br/ ><br>2) Complete Blood Count <br/ ><br>3)C reactive protein and serum Ferritin <br/ ><br>4)IL-2 and IL-6. <br/ ><br>Timepoint: 5th Day and 10th day from start of Intervention",NA,NA,NA,NA,NA,2020-11-11
1,0,NA,NA,"A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period",Control Group:Qimaifeiluoping Mixture Simulator + Respiratory Training + Rehabilitation Education Guidance;Experimental group:Qimaifeiluoping Mixture  + Respiratory Training + Rehabilitation Education Guidance;,http://www.chictr.org.cn/showproj.aspx?proj=52679,"A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period",ChiCTR,ChiCTR2000032165,2020-04-21,2020-04-25,FALSE,Interventional study,Parallel,N/A,Control Group:80;Experimental group:80;,Hubei Provincial Hospital of TCM,China,Novel coronavirus pneumonia (COVID-19),FALSE,Yes,2020-04-21,2020-04-25,31 August 2020,NA,20200421,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,18,70,Both,Xiao Mingzhong,NA,"856 Luoyu Road, Hongshan District, Wuhan, China",309452513@qq.com,+86 18908640865,Hubei Provincial Hospital of TCM,"Inclusion criteria: 1. Patients who meet the COVID-19 diagnostic criteria and discharge standards with  SARS-CoV-2 virus nucleic acid test is negative;<br>2. The pulmonary imaging in the last 1 week showed inflammation or fibrosis;<br>3. Aged 18 to 70 years old;<br>4. Signed informed consent.","Exclusion criteria: 1. History of pulmonary surgery which affected lung function;<br>2. Relying on mechanical ventilation to maintain lung function;<br>3. Complications of chronic lung disease, such as COPD;<br>4. Complications affecting heart function;<br>5. Patients with severe primary diseases may affect participation in the trial or may affect the outcome of the study by the judgment of the researcher; <br>6. Resting heart rate >120/min;<br>7. Systolic blood pressureda>180mmHgDiastolic blood pressure>100mmHg;<br>8. Unstable angina or myocardial infarction that occurred within the past month;<br>9. BMI>40;<br>10. Patients who are allergic constitution or allergy to multiple drug;<br>11. Pregnant or lactating women;<br>12. Handicapped who can't  complete the collection of efficacy evaluation indicators;<br>13. Patients who have a family history of mental illness or have had a mental illness; <br>14. Patients who are participating in other clinical trials;<br>15. According to the investigator's judgment, patients who have complicated enrollment or poor compliance, which affect the efficacy and safety assessment.",Six-minute Walk Test;lung CT;,NA,NA,NA,NA,NA,2020-04-21
0,1,NA,NA,"A Randomized, Open Label, Parallel Efficacy, Active Control, Exploratory Clinical Trial to Evaluate Efficacy and Safety of an Ayurvedic Formulation (AYUSH 64) as Adjunct Treatment to Standard of Care for the management of Mild to Moderate COVID-19 Patients",Intervention1: AYUSH 64: Dose:2 capsules (500 mg each) thrice  daily<br>Dosage form:Capsules/Tablets <br>Route of Administration:	Oral<br>Time of Administration:	Thrice a day after food<br>Anupana: Water 	<br>Duration of therapy: 30 days<br><br>Control Intervention1: Conventional standard therapy for COVID-19 positive patients: Conventional standard therapy as per ICMR/WHO parameters<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43727,To observe the effect of Ayurvedic medicine for the treatment of COVID-19,CTRI,CTRI/2020/05/025214,2020-05-15,2020-05-24,FALSE,Interventional,"Randomized, Parallel Group, Active Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Open Label",Phase 2/ Phase 3,80,Central Council for Research in Ayurvedic Sciences,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,15-05-2020,24-05-2020,2 December 2020,NA,20200515,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Sumit Shrivastva,NA,"77, Chandi Path, Sector 46B, Sector 46

 Room No. 116, Ground floor,
Shri Dhanwantry Ayurvedic Hospital",sumitpankaj@gmail.com,9781110780,Shri Dhanwantry Ayurvedic College and Hospital,"Inclusion criteria: 1.Typical clinical presentation of acute onset febrile illness with cough and a RT_PCR based laboratory confirmation test for COVID-19 <br/ ><br>2.Typical clinical presentation of acute onset febrile illness with sore throat and dry cough with or without shortness of breath in a patient from a known â??hot spotâ?? area or in close contact with a confirmed COVID-19 case with a negative laboratory test for COVID 19 and H1N1 influenza <br/ ><br>3.Patients with either sex, 18 to 75 years age <br/ ><br>4.Patients with mild-moderately severe disease <br/ ><br>5.All patients must agree not to share medication <br/ ><br>6.Patients willing to participate and sign an informed consent Understands and agrees to comply with planned study procedures. <br/ ><br>7.Agrees to the give OP swabs and venous blood for testing as per protocol. <br/ ><br>","Exclusion criteria: 1. Patients suffering from severe COVID-19 Disease as judged by a physician and fulfilling at least two of the following three criteria (i) Respiratory distress at room ambience (equal or more than 30 breaths per min) (ii) Oxygen saturation at rest equal or less than 93% (peripheral digital arterial oxymetry) and requiring oxygen support for over one hour to normalize (iii) Any of the known COVID-19 complications and emergency procedures which may require shift/admission in intensive care unit such as respiratory failure, adult respiratory distress syndrome, requirement of oxygen support for over 1 hour, requirement of mechanical ventilation, septic shock, or severe non-respiratory organ dysfunction or failure. <br/ ><br>2.Chronic, Severe, Unstable, Uncontrolled co-existent medical illness such as Diabetes, Hypertension, Cardiac disorders, liver, kidney disorders and lung disorders or other disease of concern which may put the patient at increased risk during the study  <br/ ><br>3. History of immunosuppression: solid organ or bone marrow transplant, use of immunosuppressive antimetabolic and biologic agents, intrinsic immunodeficiencies, HIV infection.  <br/ ><br>4. Active cancer diagnosis, on palliative treatment or requiring current therapy with antimetabolic agents, immunotherapy or radiotherapy. <br/ ><br>5. Patients on parenteral nutrition <br/ ><br>6. Patients with known sensitivity or contraindication to any of the ingredients of study medication <br/ ><br>7. History of bleeding haemorrhoids, haemoptysis, acid peptic diseases, ulcers and pulmonary diseases (tuberculosis, asthma, etc.) <br/ ><br>8. Patients who are likely to worsen or planed ICU admission or ventilator support due to any reason <br/ ><br>9. Pregnancy and lactation <br/ ><br>10. Participation in a drug interventional clinical drug trial of any nature in the three month period preceding onset of COVID-19 <br/ ><br>11. Participation in any other clinical trial of an experimental agent treatment for COVID-19 <br/ ><br>12. Patients on any kind of Ayurveda treatment or any other alternative and complementary medicinal systems such as Homeopathy, Unani, Siddha and in particular requiring oral therapy of any kind. <br/ ><br>13. Physician decision that involvement in the study is not in the patientÂ´s best interest <br/ ><br>","a) Mean time (days) for clinical recovery [Day of randomization to the day of clinical recovery  <br/ ><br>b) Proportion of patients showing â??clinical recoveryâ??. <br/ ><br>Timepoint: On 7th day, 15th day, 23rd day and 30th day",NA,NA,NA,NA,NA,2020-05-15
1,0,NA,NA,"A prospective, non-randomised,  single arm observational study to access the safety and effectiveness of  Siddha Sastric Medicines â?? Fixed Regimen intervention in prevention of COVID-19 disease progression of severity from COVID-19 Positive asymptomatic, mild or moderate to critical with reference to the Siddha guidelines of COVID-19 management, Ministry of AYUSH, Govt. of India at a Home Quarantine Chennai Containment Zone","Intervention1: Siddha Medicines in fixed regimen: Kaba Sura Kudineer Chooranam â?? Decoction â?? Two times daily before 30 min of meals for 14 days, <br><br>Adathodai Manapagu â?? 10 ml â?? Three times daily after meals for 14 days,<br><br>Thaleesadhi Chooranam Mathirai 500 mg â?? 2 tablet - Four times daily after meals for 14 days,<br><br>Brammhanandha bairavam 100 mg â?? 1 pill - Two times daily after meals for 7 days when fever does not subside for 7 days after administering above three medicines. This Brammhanandha bairavam 100 mg pill will not be administered initially for first 7 days. <br><br>Control Intervention1: Not Applicable: No treatment<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45363,Safety and Effectiveness of  Siddha Sastric Medicines for the Management of Covid-19,CTRI,CTRI/2020/07/026470,2020-07-10,2020-07-15,FALSE,Interventional,"Single Arm Trial
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label",Phase 2,200,Almaa Siddha Multispeciality Hospital Pvt Ltd,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,10-07-2020,15-07-2020,2 December 2020,NA,20200710,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr V THANIGAVELAN,NA,"Almaa Siddha Multispeciality Hospital Pvt. Ltd
No 10, Pillaiyar Koil Street,                                            Saidapet, Chennai
",pitchiahkumar@yahoo.com,NA,State Licensing Authority (IM),"Inclusion criteria: 1. COVID -19 Positive as determined by RT-PCR or other approved commercial or public health assay <br/ ><br>2. Willing to provide written/digital informed consent. <br/ ><br>3.COVID - 19 Positive with no clinical signs <br/ ><br>4.COVID - 19 Positive with mild symptoms â?? Sneezing, Cough, Sore Throat, Throat Pain, Malaise, Tiredness, Fever <br/ ><br>5.COVID - 19 Positive with moderate symptoms â?? Fever with cough, breathlessness but respiratory rate  <24 per minute and Oxygen saturation more than 94% at rest <br/ ><br>","Exclusion criteria: 1. Pregnant and Lactating females  <br/ ><br>2. COVID - 19 Positive with Severe symptoms â?? Respiratory distress ( >24 breath per minute), Oxygen saturation less than 94% at rest, Respiratory failure, Need of Mechanical Ventilation, Septic shock, Non respiratory organ failure  <br/ ><br>3. Chronic Renal Failure requiring dialysis (eGFR  < 30) <br/ ><br>4. Known cases of uncontrolled Diabetes ( >9% HbA1c)  <br/ ><br>5. Subjects having any medical or surgical condition that would require immediate medical or surgical intervention at the time of screening  <br/ ><br>6. Subjects having immune compromised status like HIV, Hepatitis, Tuberculosis, Cancer etc.   <br/ ><br>7. Subjects taking Steroid treatment and or any kind of immunosuppressive therapy <br/ ><br>8. Subjects participating in any other clinical study or having participated in any other study 1 month prior to screening in the present study.  <br/ ><br>9. Subjects having a past history of allergy to any medicine that is part of the Siddha intervention. <br/ ><br>10. Subjects with bleeding disorders and severe anaemia(Hb -  <7 g/dL) <br/ ><br>","1.RT-PCR will be the gold standard used to assess sero conversion - Positive to negative which is the main outcome of this study. This will be used to establish the effect of the intervention.  <br/ ><br> <br/ ><br>To support this, reduction in the severity of disease and reductions of symptoms will be documented.    <br/ ><br> <br/ ><br>2.Reduction in severity of the disease will be measured using Immune Status Questionnaire (ISQ).  <br/ ><br> <br/ ><br>3.Reductions of symptoms will be documented using case report form  <br/ ><br>Timepoint: 14 days",NA,NA,NA,NA,NA,2020-07-10
0,1,NA,NA,Whole lung Irradiation as a Novel treatment for COVID-19 - WIN COVID-19,"Intervention1: Low Dose Radiation therapy in addition to standard pharmacological therapy: Low dose radiotherapy using a Linear accelerator to bilateral whole lungs as a single fraction treatment with a dose of 0.5 Gy in addition to pharmacological therapy based on guidelines devised by Ministry of Health and Family welfare, India<br>Dexamethasone 6mg IV Once daily for 10 days, (Alternative: Methylprednisolone 80mg IV BD for 10 days)<br>Enoxiparin 60mg s/c Once Daily for 5 days (dose adjusted based on D-dimer levels), <br>Remdesvir 200mg IV Once daily on day 1 followed by 100mg IV Once daily for next 4 days, further continuance based on clinical response,  <br>Convalescent plasma One or two units (approximately 200-250ml per unit),   <br>Tocilizumab 400mg IV as a single dose (repeat dose in 12 to 24 hours if patientâ??s condition has not<br>improved), Vitamin D 60,000U /week, <br>Vitamin C 1500 mg/day,<br>Zinc,<br>Paracetamol, Anti-tussives, Antibiotics,<br>Oxygen supplementation. <br>Adjunctive therapies : IV thiamine,IV vitamin C, N acetyl cysteine, Ulinastatin, Sepsivac (mycobacterium w), high dose statins.  <br>Salvage therapies : Pulse therapy of steroids, Cytosorb-hemoperfusion, Pirfenidone,Alteplase.<br>The pharmacologic therapy is individualized on a case by case basis.<br>Control Intervention1: Standard Pharmacological Therapy only: Pharmacological therapy based on guidelines devised by Ministry of Health and Family welfare, India.<br>Dexamethasone 6mg IV Once daily for 10 days (Alternative: Methylprednisolone 80mg IV BD for 10 days), Enoxiparin 60mg s/c Once Daily for 5 days (dose adjusted based on D-dimer levels), Remdesvir 200mg IV Once daily on day 1 followed by 100mg IV Once daily for next 4 days, further continuance based on clinical response, Convalescent plasma One or two units (approximately 200-",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48730,Low dose lung X-ray therapy for COVID-19,CTRI,CTRI/2020/10/028597,2020-10-23,2020-11-06,FALSE,Interventional,"Randomized, Parallel Group, Active Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:On-site computer system  Blinding and masking:Open Label",Phase 2,61,Harshamitra Superspecialty Cancer Centre and Research Institute,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,23-10-2020,06-11-2020,2 December 2020,NA,20201023,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Vivek Sundaram,NA,"No.17, Room no.2, Ground floor, Department of internal medicine, COVID block, E.V.R. Road, Puthur, Trichy, Tamilnadu -
620017
",drsasipriyahmitra@gmail.com,7373642777,Harshamitra Oncology Private Limited,"Inclusion criteria: 1. Adult patients with RT-PCR proven COVID-19 with moderate to severe pneumonia with fewer than 14 days of symptom onset that warranted hospitalization and currently receiving standard medication for COVID-19 at appropriate doses which would include, among others, antivirals, corticosteroids, or anti-IL-6 tocilizumab. <br/ ><br>and <br/ ><br>2. moderate to severe dyspnoea, respiratory frequency equal to or greater than 30/min, oxygen saturation without supplemental O2 supply SpO2 94% or less, PaO2/FiO2 ratio or PaFiO2 ratio between 200 to 300 or SpO2/FiO2 ratio 315 or less if PaO2 is not available <br/ ><br>and/or <br/ ><br>3. laboratory abnormalities such as C-reactive protein >100 mg/L or D-dimer >1000 ng/ml or IL-6 >50 IU or suspected cytokine release syndrome  <br/ ><br> <br/ ><br>(Criteria 1 and 2 are mandatory and 3 is optional)","Exclusion criteria: 1. Patients on ventilators (invasive/non-invasive) <br/ ><br>2. Prior lobectomy or pneumonectomy <br/ ><br>3. Prior thoracic radiotherapy resulting in a maximum lung dose of 100 cGy or higher within 14 days of enrollment <br/ ><br>4. Prior chemotherapy or other systemic therapy with potential for pulmonary toxicity or radio sensitization within 14 days or 5 half-lives, whichever is greater, of enrollment, e.g., bleomycin, gemcitabine <br/ ><br>5. Prior cancer immunotherapy with an immune checkpoint inhibitor within 60 days of enrollment <br/ ><br>6. Severe pre-existing heart disease, e.g., New York Heart Association (NYHA) functional class 3 (or higher) congestive heart failure <br/ ><br>7. History of bone marrow or solid organ transplantation <br/ ><br>8. Known history of autoimmune collagen vascular disease, e.g., scleroderma <br/ ><br>9. Known hereditary syndrome with increased sensitivity to ionizing radiation, e.g., ataxia-telangiectasia or Fanconi anemia <br/ ><br>10. Pregnancy <br/ ><br>11. Inability to be positioned supine and flat for radiation planning and delivery <br/ ><br>12. Inability to provide informed consent or lack of an authorized representative who can provide informed consent","The primary end-point will be to evaluate the efficacy of low-dose pulmonary irradiation as an adjunctive treatment in interstitial pneumonia in patients with COVID-19 by improving the PaO2-FiO2 by 20% measured 48-72h after treatment with respect to baseline pre-irradiation measurementTimepoint: 6 hours,day 1, day 2, day 3, day 4, day 7",NA,NA,NA,NA,NA,2020-10-23
1,0,NA,NA,The Effect and Safety of cytokine removal therapy in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) adult patients: a Prospective Open-label Study,Case series:cytokine removal therapy with Cytosorb;,http://www.chictr.org.cn/showproj.aspx?proj=50452,Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19),ChiCTR,ChiCTR2000030475,2020-03-03,2020-03-04,FALSE,Interventional study,Single arm,0,Case series:19;,"Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College",China,Novel Coronavirus Pneumonia (COVID-19),FALSE,Yes,2020-03-03,2020-03-04,9 March 2020,NA,20200303,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,18,NA,Both,Xuemei Li,NA,"1 Shuai-Fu-Yuan, Dongcheng District, Beijing, China",lixmpumch@126.com,+86 13911467356,"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","Inclusion criteria: 1. Written informed consent from patients or representative;<br>2. Aged over 18<br>3. Fullfill the diagnostic criteria of critically ill 2019-nCoV Respiratory Disease;<br>2019-nCoV diagnosis confirmed by the combination of epidemiology, clinical manifestation and virus PCR results of respiratory specimen;<br>Critically ill patients should include one of the followings at least:<br>1) respritary failure, mechanical ventilation required;<br>2) shock;<br>3) complicated with other organ failures, require ICU admission.","Exclusion criteria: 1. Respiratory failure explained with other lung conditions, including influenza virus, bacterial infection, fungi infection, non-infectious causes;<br>2. Comorbidities including lupus, vasculitis, APS et al.;<br>3. Concurrent use of anti-IL6 receptor antibody;<br>4. Malignancy;<br>5. Pregnancy;<br>6. there is potential of transfer to other hospital during the trial;<br>7. Other potential conditions determined by the investigators.",28 day mortality;,NA,NA,NA,NA,NA,2020-03-03
0,1,NA,NA,Evaluation of therapeutic effects of oral eucalyptus tablets on the treatment process of patients with Covid 19 infection.,"Intervention 1: Intervention group: Patients undergoing intervention with Eucalyptus soft oral capsule from Barij Essential Oil Company containing Eucalyptus essential oil (Eucalyptus globulus) Active ingredients 8 (Cineol (Eucalyptol), Alpha-Pinene, Lemonene) in accordance with the approved drug catalog of the Food and Drug Administration 8 hours for 5 days. Intervention 2: Control group: Patients are not intervened.",http://en.irct.ir/trial/50912,Evaluation of effects of eucalyptus tablets on the process of covid 19 disease,IRCT,IRCT20200913048701N1,2020-09-22,2020-09-22,FALSE,interventional,"Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, after obtaining informed consent from eligible individuals, individuals will be randomly divided into two groups using the number table method. In this way, patients who are candidates for inclusion in the study, after reviewing the inclusion and exclusion criteria and obtaining informed consent, a number will be given to people using the software, and based on this random number, people will be given one of the two The study group will belong, Blinding description: This study is three-way blind, so that the subject and the clinician conducting the research who monitors the patients and the statistical analyzer are unaware of the status of the two groups assigned to the study. Labels on medicine packages will be removed. The subject is not aware of the status of assignment to groups. The researcher who makes clinical and diagno",3,50,Iran University of Medical Sciences,Iran (Islamic Republic of),COVID-19 disease. <br>COVID-19;U07.1,FALSE,Yes,2020-09-22,2020-09-22,6 October 2020,NA,20200922,12/3/2020 5:31:55 PM,IRCT,Not Recruiting,No,40 years,60 years,Both,Hossein Shirazi,NA,"No. 49, Taleghani Ave., Miri Blvd., Varamin Town",shirazi.h@iums.ac.ir,+98 21 3625 6451,Iran University of Medical Sciences,Inclusion criteria: Patients between 40 and 60 years of age with new coronavirus infection 2019 who have been admitted to Firoozabadi Hospital.,Exclusion criteria: Age over 60 years<br>Age under 40 years<br>No hospitalization<br>No infection with coronavirus 2019,"Blood oxygen level (SPO2%). Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: Pulse oximeter device.;Inflammatory index CRP. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.;Cough. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: Qualitative (mild-moderate-severe).;Blood lymphocyte count. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.;White blood cell count. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.",NA,NA,NA,NA,NA,2020-09-22
1,0,NA,NA,"Randomized, Prospective, Open-label, Controlled Parallel-group Trial Investigating the Efficacy of Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat the Systemic Inflammatory Response Against SARS-CoV2 and the Associated Coagulopathy",Device: therapeutic plasmaexchnage,https://clinicaltrials.gov/show/NCT04613986,Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19,CT.gov,NCT04613986,2020-11-02,2020-12-01,TRUE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).,N/A,20,University of Zurich,NA,Severe Covid-19,FALSE,Yes,02/11/2020,December 2020,16 November 2020,PExCoV,20201102,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,99 Years,All,NA,NA,NA,NA,NA,NA,"<br>        Inclusion Criteria:<br><br>          -  Proven SARS-CoV2 infection<br><br>          -  Severe Covid-19 (indicated by respiratory failure requiring invasive mechanical<br>             ventilation)<br><br>          -  Evidence of coagulopathy (indicated by D-dimer > 10 mg/L)<br><br>          -  Evidence of systemic inflammation (CRP > 100 mg/L , ferritin > 500 ng/mL)<br><br>        Exclusion Criteria:<br><br>          -  • Participation in another study with investigational drug within the 30 days<br>             preceding and during the present study,<br><br>               -  Previous enrolment into the current study.<br><br>               -  Extra corporeal membrane oxygenation (ECMO)<br>",NA,relative ADAMTS13 deficiency,NA,NA,NA,NA,NA,2020-11-02
0,1,NA,NA,Efficacy of the myrtle (Myrtus Communis) syrup in the treatment of suspected novel coronavirus pneumonia (COVID-19),"Intervention 1: Intervention group: Patients in this group receive medication for treatment of Covid-19 based on Fifth Edition of the Novel Corona Virus Guidelines, in addition they recieve myrtle syrup for 5 days  (Patients daily boil the contents of a pack containing 10 grams of myrtle fruit and 10 grams of sugar in 3 glasses of water gently to stay 2 glasses, then smooth it and drink one glass in the morning and one glass in the evening.). Intervention 2: Control group: Patients in this group receive medication according to the novel Corona virus country guideline version 5.",http://en.irct.ir/trial/46721,Efficacy of the myrtle syrup in the treatment of novel corona,IRCT,IRCT20180923041093N3,2020-03-28,2020-04-02,FALSE,interventional,"Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be selected according to the inclusion criteria and then randomly assigned to the experimental and control groups according to the random sequence obtained through random allocation software.",3,70,Kerman University of Medical Sciences,Iran (Islamic Republic of),COVID-19. <br>COVID-19;U07.1,FALSE,Yes,2020-03-28,2020-04-02,15 June 2020,NA,20200328,12/3/2020 5:31:55 PM,IRCT,Not Recruiting,No,18 years,65 years,Both,Maryam Azimi,NA,"Crossroad Amir kabir, Jomhuri eslami Blvd",dr.azimm@gmail.com,+98 34 3211 0860,Kerman University of Medical Sciences,Inclusion criteria: <br>                18-65 years old<br>                Developed mild to moderate COVID-19 based on Fifth Edition of the Novel Corona Virus Guidelines<br>                Candidate for outpatient treatment<br>,Exclusion criteria: <br>                Allergy to myrtle<br>                Asthma or allergy<br>                Hypertension<br>                Diabetes<br>                Pregnancy/lactation<br>                Congestive heart failure<br>                Chronic renal failure<br>                Chemotherapy<br>                Taking Corticosteroid<br>                Immune deficiency<br>,Temperature. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Termometer.;Cough (severity-frequency). Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Fisman Cough Severity Score.;Weakness. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Muscular pain. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Asking patients using visual analog scale (VAS).;Respiratory rate. Timepoint: 0-1-2-3-4-7-14 days after starting intervention. Method of measurement: Counting the number of breaths per minute.,NA,NA,NA,NA,NA,2020-03-28
0,1,NA,NA,"Immunological efficacy of Jinhua Qinggan Granule for COVID-19: an open-label, single-arm trial - COVID-19/Jinhua Qinggan Granule",Duration: 1 hour<br>Dose: JHQG Granule 5 g<br>Number of doses: 1,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046108,Immunological efficacy of Jinhua Qinggan Granule for COVID-19,JPRN,JPRN-UMIN000040407,2020-05-15,2020-05-15,FALSE,Interventional,Single arm Non-randomized,Not selected,15,"Administration Department, Takanawa Clinic",Japan,COVID-19,FALSE,Yes,15/05/2020,2020/05/15,15 June 2020,NA,20200515,12/3/2020 5:31:55 PM,JPRN,Not Recruiting,No,20years-old,70years-old,Male and Female,Tomoka,Ebisui,"1-22-17, Kitashinagawa, Shinagawa-ku, Tokyo",jimukyoku@takanawa-clinic.com,03-6433-3165,Takanawa Clinic Administration Department,Inclusion criteria:,"Exclusion criteria: Current infectious, inflammatory, or immune-related diseases",Plasma cytokine levels 1 hour after the administration of JHQG,NA,20/05/2020,NA,NA,NA,2020-05-15
1,0,NA,NA,Modulation of Gut Microbiota With NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes Mellitus,Drug: NBT-NM108;Other: Usual Care Only,https://clinicaltrials.gov/show/NCT04540406,NBT-NM108 as an Early Treatment of Suspected or Confirmed COVID-19 in Patients With Prediabetes or Type 2 Diabetes,CT.gov,NCT04540406,2020-09-03,2020-10-01,FALSE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,100,Notitia Biotechnologies Company,United States,Suspected or Confirmed COVID-19,FALSE,Yes,03/09/2020,"October 1, 2020",28 September 2020,NA,20200903,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,69 Years,All,; ; ;,"Asa Oxner, MD;Liping Zhao, PhD;Jeffrey Zhao;Asa Oxner, MD",NA,;;clinicaltrials@notitiabio.com;aoxner@usf.edu,;;833-668-4842;813-974-1440,University of South Florida;Rutgers University;,"<br>        Inclusion Criteria:<br><br>          -  Aged between 18 to 69 (inclusive)<br><br>          -  Have prediabetes or T2DM<br><br>          -  Have mild to moderate COVID-19-like symptoms based on the symptom list from the CDC<br>             (updated May 13, 2020) and the severity categorization from FDA (20):<br><br>               1. Mild COVID-19<br><br>                    -  Fever or chills, cough, shortness of breath or difficulty breathing,<br>                       fatigue, muscle or body aches, headache, new loss of taste or smell, sore<br>                       throat, congestion or runny nose, nausea or vomiting, and diarrhea<br><br>                    -  No clinical signs indicative of moderate, severe, or critical illness<br>                       severity<br><br>               2. Moderate COVID-19<br><br>                    -  Symptoms of moderate illness with COVID-19 could include any symptom of mild<br>                       illness or shortness of breath with exertion<br><br>                    -  Clinical signs suggestive of moderate illness with COVID-19, such as<br>                       respiratory rate = 20 breaths/min, oxygen saturation level > 93% on room air<br>                       at sea level, heart rate = 90 beats/min<br><br>                    -  No clinical signs indicative of severe or critical illness severity<br><br>          -  Directed to home isolation by the study physician<br><br>          -  Confirm study enrollment within 4 days of symptoms onset<br><br>          -  Practice acceptable contraception, i.e., continue with current methods if participants<br>             are already practicing contraception, otherwise, participants must agree to practice<br>             contraception with a barrier method (male or female condom) or abstinence, from Day 0<br>             to Day 35 or 7 days after the last dose of NBT-NM108 if they do not complete the<br>             28-day intervention.<br><br>          -  Have access to a smartphone, tablet, computer, or other qualifying internet-enabled<br>             device and daily internet access<br><br>          -  Understand and be able to follow written and oral instructions in English<br><br>          -  Provide informed consent<br><br>        Exclusion Criteria:<br><br>          -  Receiving vancomycin monotherapy or oral broad-spectrum antibiotics<br><br>          -  Inability to receive oral fluids<br><br>          -  Self-reported allergy or intolerance to any ingredients in NBT-NM108<br><br>          -  Surgery involving the intestinal lumen within the last 30 days<br><br>          -  Documented diagnosis of celiac disease, inflammatory bowel disease or irritable bowel<br>             syndrome<br><br>          -  Pregnancy or breastfeeding<br><br>          -  Bariatric surgery<br><br>          -  Chronic lung disease or moderate/severe asthma<br><br>          -  Heart failure, coronary artery disease, congenital heart disease, cardiomyopathies or<br>             pulmonary hypertension<br><br>          -  Chronic kidney disease on dialysis<br><br>          -  Chronic liver disease (cirrhosis)<br><br>          -  Immunocompromised, e.g. cancer treatment, bone marrow/organ transplant, immune<br>             deficiency, poorly controlled HIV/AIDS, prolonged use of steroids or other<br>             immunosuppressant medications<br>",NA,Gut Microbiota Composition,NA,NA,NA,NA,NA,2020-09-03
0,1,NA,NA,"Immunological Effect of the drug â??Immuneâ??- an Ayurveda medication in COVID-19 patients
","Intervention1: Immune-combination of Devadaaru, Aswagandha, Yashthimadu and Jeevanthi which are already proven drugs: 6 drops in 50 ml of water every 4 hours <br>Administered for 15 days<br><br>Control Intervention1: placebo-distilled water: 6 drops in 50 ml of water every 4 hours <br>administered for 15 days<br><br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48593,"Effect of the drug â??Immuneâ??- an Ayurveda medication in COVID-19 patients
",CTRI,CTRI/2020/10/028471,2020-10-19,2020-11-02,FALSE,Interventional,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Random Number Table  Method of allocation concealment:Alternation  Blinding and masking:Participant and Investigator Blinded",N/A,50,NGR Vishnu Sri,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Health Condition 2: B999- Unspecified infectious disease
",FALSE,Yes,19-10-2020,02-11-2020,2 December 2020,NA,20201019,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Sailaja Vani,NA,"Department- AYUSH
Division- Ayurveda
Room no-15, 5th floor, OPD Block, Esic medical college and hospital
7-1-634, survey no.121/1, National highway 65, Sanjeev reddy nagar , Sanathnagar, Hyderabad",dr.sudhabala78@gmail.com,7702031889,"ESIC Medical college, Sanathnagar, Hyderabad",Inclusion criteria: Mild to Moderate COVID- 19 confirmed patients of age greater than 20 years and upto 58 years and willing to participate with consent  <br/ ><br>,"Exclusion criteria: Who are not willing to participate, with co-morbidities, pregnant and lactating women",To detect the  rise in antibody titre with the drug intake and  reduction in inflammatory markers with the drug intake.Timepoint: 2 months,NA,NA,NA,NA,NA,2020-10-19
0,1,NA,NA,Efficacy of Ayurveda Intervention (AYUSH 64) as add-on therapy in COVID 19 patients - An open label randomized controlled trial,Intervention1: AYUSH 64: AYUSH 64 02 Capsules of 500mg each orally thrice daily for 14 days as add-on therapy to supportive and symptomatic allopathic treatment for COVID 19 patients<br>Control Intervention1: Control arm: Supportive or symptomatic allopathic treatment as per guideline of study site hospital for COVID 19 patients	<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44386,Effect of AYUSH 64 in COVID 19,CTRI,CTRI/2020/06/025855,2020-06-13,2020-06-15,FALSE,Interventional,"Randomized, Parallel Group Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Open Label",Phase 2,200,IPGT and RA,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,13-06-2020,15-06-2020,2 December 2020,NA,20200613,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Sagar M Bhinde,NA,Room no 533 kaumarbhritya department IPGT and RA Gujarat Ayurved University Jamnagar,kaurmandip22@yahoo.com,9427572306,IPGTRA Jamnagar,Inclusion criteria: Asymptomatic or minimal symptomatic COVID 19 patients Patients having 0 to 4 score as per the WHO ordinal scale for clinical improvement  <br/ ><br>Age 18 to 70years <br/ ><br>Patients who can take oral medicine <br/ ><br>Patients who are ready to give written consent <br/ ><br>,Exclusion criteria: Age below 18 and above 70years <br/ ><br>Patients having severe symptoms of COVID19 <br/ ><br>Patients on mechanical ventilator or organ support <br/ ><br>Patients do not able to take oral medication <br/ ><br>Pregnant and lactating women <br/ ><br>Oncological diseases and other systemic uncontrol conditions such as HTN diabetes etc <br/ ><br>Liver or kidney malfunctions. <br/ ><br>Severe pneumonia Acute respiratory distress syndrome Sepsis and Septic Shock  <br/ ><br>,Ordinal scale for Clinical improvement as per WHO  <br/ ><br>Duration on mechanical ventilator <br/ ><br>All cause mortality <br/ ><br>Timepoint: 0 7 14 and 28th day,NA,13/08/2020,NA,NA,NA,2020-06-13
0,1,NA,NA,Randomized controlled trial of prevention for COVID-19 with Kampo medicines - IMJEDI-P1 Study,"Participants are randomly divided into two groups, a herbal medicine group, and a placebo group. Participants in each group continue to take 9 tablets twice a day orally before or between meals for 8 weeks (56 days).",https://jrct.niph.go.jp/latest-detail/jRCTs031200150,Prophylactic study for COVID-19 with Kampo medicines,JPRN,JPRN-jRCTs031200150,2020-10-14,2020-10-14,FALSE,Interventional,"randomized controlled trial, single blind, placebo control, parallel assignment, prevention purpose",3,6000,Namiki Takao,Japan,COVID-19 <br>Respiratory Tract Infections,FALSE,Yes,14/10/2020,14/10/2020,4 November 2020,NA,20201014,12/3/2020 5:31:55 PM,JPRN,Recruiting,No,>= 20age old,<= 75age old,Both,Takao,Namiki,1-8-1 Inohana Chuo-ku,tnamiki@faculty.chiba-u.jp,+81-43-226-2984,Chiba Univerity Hospital,Inclusion criteria: 1) Age from 20 to 75 years old (at the time of registration)<br>2) Asymptomatic and body temperature below 37.0 degrees Celsius (at the time of registration)<br>3) Capable of eating orally,"Exclusion criteria: 1)Previous upper respiratory inflammation due to viral infection (including suspected COVID-19)<br>2)Taking immunosuppressants<br>3)Allergic to any Kampo medicines <br>4)History of hypokalaemia, severe hypertension, severe liver dysfunction, and interstitial pneumonia<br>5)Regularly taking other Kampo medicines<br>6)Pregnant or possibly pregnant<br>7)Participating in other research<br>8)Judged to be unsuitable for this study by the doctor in charge",The number of COVID-19 PCR positives with symptoms,NA,NA,NA,NA,NA,2020-10-14
1,0,NA,NA,"A prospective, non-randomized, single-arm interventional study to assess the safety and efficacy of Siddha Sasthric Medicines â?? Fixed Regimen in the prevention of COVID-19 disease progression of asymptomatic, and mild at Siddha COVID Care Centre, Chennai, 2020 (SSM-FiRe) - SSM-FiRe",Intervention1: Kaba Sura Kudineer: 60ml BD for 14 days<br>Intervention2: Tab. Amukkarachooranam: 2 BD for 14 days<br>Intervention3: Tab. Athimathuram: 2 BD for 14 Days<br>Intervention4: Tab. Brahmanandha Bairavam: 100mg 1BD for 14 days<br>Intervention5: Adathodai Manappagu: 10ml with 30ml water  BD for 14 days<br>Intervention6: Thippili Rasayanam: 5gm BD for 14 days<br>Intervention7: Notchi Kudineer: 60ml BD for 14 Days<br>Control Intervention1: Not Applicable: Not Applicable<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45318,A clinical trial to study the effect and safety of the Siddha medicines in patients with Corona Virus disease,CTRI,CTRI/2020/07/026471,2020-07-10,2020-07-20,FALSE,Interventional,"Single Arm Trial
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable",Phase 2,60,The Directorate of Indian Medicine and Homoeopathy,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,10-07-2020,20-07-2020,2 December 2020,NA,20200710,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr D Sasikumar,NA,"Research & Development Wing
Directorate of Indian Medicine and Homoeopathy, Arumbakkam, Chennai",siddha2k6@gmail.com,9443579540,Siddha Central Research Institute,"Inclusion criteria: COVID -19 Positive as determined by RT-PCR or other approved commercial or public health assay <br/ ><br>Willing to provide written/digital informed consent. <br/ ><br>COVID - 19 Positive with no clinical signs <br/ ><br>COVID - 19 Positive with mild symptoms â?? Fever, Cough, Sneezing, Sore Throat, Throat Pain, Malaise, Tiredness <br/ ><br>","Exclusion criteria: Pregnant and lactating females  <br/ ><br>COVID - 19 Positive with Severe symptoms â?? Respiratory distress ( >24 breath per minute), Oxygen saturation  <90% at rest, Respiratory failure, Need of Mechanical Ventilation, Septic shock, Non-respiratory organ failure  <br/ ><br>Chronic Renal Failure requiring dialysis (eGFR  < 30) <br/ ><br>Known cases of uncontrolled Diabetes ( >10% HbA1c)  <br/ ><br>Subjects having any medical or surgical condition that would require immediate medical or surgical intervention at the time of screening  <br/ ><br>Subjects having immune-compromised status like HIV, Hepatitis, Tuberculosis, Cancer, etc.   <br/ ><br>Participants taking Steroid treatment and or any kind of immunosuppressive therapy <br/ ><br>Participants participating in any other clinical study or having participated in any other study 1 month prior to screening in the present study.  <br/ ><br>Participants having a past history of allergy to Siddha medicine. <br/ ><br>Participants with Hb -  <7 g/dL",Reduction in incidence of clinical symptoms of COVID-19 or Negative conversion of SARS-CoV-2Timepoint: 14 Days,NA,NA,NA,NA,NA,2020-07-10
1,0,NA,NA,A Pilot study to estimate the effectiveness of Ayurvedic intervention in COVID-19 positive cases,"Intervention1: Ayurvedic medicines: 1. Sanshamani Vati <br>(Tinospora cordifolia)	 		1gm BD with 50ml Nagaradi kwath(Decoction of Zingiber officinale -2 part, Terminalia chebula- 4 part, Tinospora cordifolia-6 part in quantity)<br><br>2.Amalaki  Churna <br>( Powder of Phyllanthus emblica)3gm with water<br>once a day at 5pm<br>3.Golden  Milk (100ml of milk with 3gm of Curcuma longa) at 9pm. 	<br>Intervention2: Ayurveda Protocol: 1. Sanshamani Vati (Tinospora cordifolia) 1gm BD with 50ml Nagaradi kwath(Decoction of Zingiber officinale -2 part, Terminalia chebula- 4 part, Tinospora cordifolia-6 part in quantity) 2.Amalaki Churna ( Powder of Phyllanthus emblica)3gm with water once a day at 5pm 3.Golden Milk (100ml of milk with 3gm of Curcuma longa) at 9pm.<br>all to be taken orally <br>Duration 14 days<br>Control Intervention1: Not applicable: Not applicable<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43892,effect of Ayurvedic intervention in COVID-19 positive cases,CTRI,CTRI/2020/05/025276,2020-05-20,2020-05-29,FALSE,Interventional,"Single Arm Trial
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable",Phase 3,50,Ch Brahm Prakash Ayurved Charak Sansthan,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,20-05-2020,29-05-2020,2 December 2020,NA,20200520,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Arun Gupta,NA,"CBPACS, Khera Dabar, New Delhi 110073 Room no 142
Panchakarma Department
CBPACS
New Delhi 110073",arun24@hotmail.com,9999155377,Chaudhary Brahm Prakash Ayurved Charak Sansthan,Inclusion criteria: 1.	Willingness to participate in the study and provide the informed consent. <br/ ><br>2.	Isolated asymptomatic cases that have been tested positive for SARS-CoV2 virus. <br/ ><br>,Exclusion criteria: 1.	Cases presenting with severe symptoms of COVID-19. <br/ ><br>2.	COVID-19 positive cases participating as subjects in the interventional arm of other COVID-19 clinical study. <br/ ><br>,1.	Time taken and number of patients progressing from asymptomatic to symptomatic condition. <br/ ><br>	Timepoint: baseline <br/ ><br>Daily <br/ ><br>14 days,NA,17/06/2020,NA,NA,NA,2020-05-20
0,1,NA,NA,"A Phase 2 evaluation of the efficacy of homoeopathic remedy Zincum Muriaticum as an adjuvant therapy to standard of care in adult patients with moderate to severe COVID-19: Randomized, double-blind, parallel group, placebo controlled, multicenter trial (ZIMCOV)","Intervention1: Zincum muriaticum 200C: Sucrose globules premedicated with liquid potency will be administered per orally. A single dose will consist of two globules of size 40. The dosage will be six times a day at an interval of 3 hours between two successive doses<br>In case patents are intubated, they will receive reconstituted dilution PO<br>Dosing frequency will be02 drops two hourly eight times a day.<br>Upon discharge, the dosage will be three times a day at an interval of 6 hours between two successive doses<br><br>Control Intervention1: Identical Plaebo: Sucrose globules premedicated with liquid potency will be administered per orally. A single dose will consist of two globules of size 40. The dosage will be six times a day at an interval of 3 hours between two successive doses<br>In case patents are intubated, they will receive reconstituted dilution PO<br>Dosing frequency will be02 drops two hourly eight times a day.<br>Upon discharge, the dosage will be three times a day at an interval of 6 hours between two successive doses<br><br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46189,Investigation of effect of homoeopathic remedy as add on therapy to standard of care (regular treatment) in adult patients with moderate to severe COVID-19,CTRI,CTRI/2020/08/027005,2020-08-05,2020-08-12,FALSE,Interventional,"Randomized, Parallel Group, Placebo Controlled Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Centralized  Blinding and masking:Participant and Investigator Blinded",Phase 2,96,Homoeocon Foundation,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,05-08-2020,12-08-2020,2 December 2020,NA,20200805,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Anil Khurana,NA,"61-65 Institutional Area, Opp D Block, Janak Puri, New Delhi",ccrhindia@gmail.com,011-28525523,Central Council for Research in Homoeopathy,"Inclusion criteria: A subject will be considered eligible for inclusion in this study only if ALL of the following criteria apply: <br/ ><br>1. Hospitalized patient with laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) (or any other confirmatory test to diagnose SARS-CoV-2 infection if there is such change in guidelines issued time to time by the Government of India, Task Force for COVID or any other concerned authority/body assigned for this purpose) as documented by either of the following: <br/ ><br>PCR positive in sample collected  < 72 hours prior to randomization;                        OR <br/ ><br>PCR positive in sample collected â?¥ 72 hours prior to randomization with documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking  >24 hours, etc.)   <br/ ><br>2. Subject (or legally acceptable representative) understands and agrees to comply with planned study procedures and provides informed consent prior to initiation of study procedures. <br/ ><br>3. Male or non-pregnant female adult â?¥18 years of age at time of enrolment. <br/ ><br>4. Illness with â?¤12 days duration, and at least one of the following: <br/ ><br>Radiographic infiltrates by imaging captured during the period between date of admission to date of enrolment that is chest x-ray, CT scan, lung ultrasound. <br/ ><br>Presence of clinical features of dyspnea and or hypoxia, fever cough including Respiratory rate  > 24 breaths/min OR SpO2  < or equal to 94 on room air <br/ ><br>Requiring supplemental oxygen <br/ ><br>Requiring HFNO/NIV <br/ ><br>5. Women of childbearing potential must agree either to abstinence or to use at least one primary form of contraception not including hormonal contraception from the time of screening till end of the study. <br/ ><br>6. Subject (or legally acceptable representative) agrees to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 till end of this study. <br/ ><br>7. Subject (or legally acceptable representative) is willing to be a study participant and to accept randomization to any assigned treatment arm. <br/ ><br> <br/ ><br> <br/ ><br> <br/ ><br>","Exclusion criteria: 1. Physician makes a decision that trial involvement is not in patientâ??s best interest, or there is any condition that does not allow the protocol to be followed safely. <br/ ><br>2. There is anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours. <br/ ><br>3. Patient already in another clinical trial of an experimental treatment for COVID-19 <br/ ><br>4. Patient has a PaO2/FiO2 ratio  < 200 or is requiring IMV/ECMO at baseline.",TTR (Time to Recovery)Timepoint: Censored at Day 28 <br/ ><br>TTR is defined as the time (in days) from randomization of study treatment (active or placebo) until Day of recovery. Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the eight category ordinal scale,NA,NA,NA,NA,NA,2020-08-05
0,1,NA,NA,The effect of garlic and cinnamon essential oil on the treatment of patients with  corona (COVID-19),"Intervention 1: Intervention group: Recipient of garlic essential oil. Patients in the intervention group will take the drug prepared from garlic for 1 week. A drop of garlic made by Amin Pharmaceutical Company is consumed ten drops daily for a week. Each 10 drops of Garlic contains 250 grams of garlic extract. It should be noted that patients will receive routine medication for coronary artery disease. The trained nurse will perform the intervention. Intervention 2: Control group: No intervantion. Intervention 3: Intervention group: Intervention group: Recipients of cinnamon essential oil. Patients of the second intervention group will take cinnamon medicine for 1 week. Cinnamon drops made by Zardband pharmaceutical company .It will be use three times a day and 5 drops in a glass of water, tea each time. It should be noted that patients will receive routine medication for the treatment of coronary heart disease.",http://en.irct.ir/trial/49481,Garlic and cinnamon on the treatment of patients with corona,IRCT,IRCT20200705048011N1,2020-08-16,2020-08-22,FALSE,interventional,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.",N/A,45,Sabzevar University of Medical Sciences,Iran (Islamic Republic of),"Covid-19. <br>Coronavirus infection, unspecified;B34.2",FALSE,Yes,2020-08-16,2020-08-22,7 September 2020,NA,20200816,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,10 years,no limit,Both,Nasrin Fazel,NA,"No 2,Tohid Shahr Ave, Campus University Building,Sabzevar",shohreh1368@yahoo.co.uk,+98 51 4401 1000,Sabzevar University of Medical Sciences,Inclusion criteria: Inclusion criteria include all patients with corona virus who had a positive RT-PCR test.,"Exclusion criteria: Exclusion criteria for patients with corona negative test<br>Those who are not willing to continue participating in the study.<br>Patients with allergies to garlic and cinnamon,<br>Patients taking anticoagulants,  having diabetes,<br>Insomnia,<br>Pemphigus, asthma,<br>Transplantation,<br>Pregnancy.",Headache. Timepoint: The first day and the last day of the intervention. Method of measurement: Visual Analogue Scale.;Body pain. Timepoint: The first day and the last day of the intervention. Method of measurement: Visual Analogue Scale.,NA,NA,NA,NA,NA,2020-08-16
0,1,NA,NA,"Evaluating the therapeutic effect of a mixed herbal drink of Marshmallow and Licorice on COVID 19 patients, A double blind clinical trial","Intervention 1: Intervention group:After routine treatment , the main group will be received the drug of the study . drugs are in the sacher form. every sacher contain 2.5 gram of Marshmallow and 2.5 gram of Licorice. For 10 days Patients should infuse the contents of one packet with 250 cc of boiling water for 10 minutes every 12 hours, then strain and sip. Intervention 2: Control group: after routine treatment, the control group willl be received the placebo. they are in the sacher form. The contents of each package of placebo is 5 grams of starch powder. For 10 days,  patients should infuse the contents of one packet with 250 cc of boiling water for 12 minutes every 12 hours, then strain and sip.",http://en.irct.ir/trial/46903,Evaluating the effect of Marshmallow and Licorice on COVID 19 patients,IRCT,IRCT20200404046937N1,2020-04-09,2020-04-09,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into two Therapeutic groups by random method and used 6 blocks method.
Individuals are the randomization unit and randomization tools are statistical soft ware, make a random sequence is by using  statistical soft ware 
allocation concealment  is by assigning unique codes, Blinding description: double blind: Supervisor and the participants are blind to the prescription drug of the target group and the control group
The drugs of both groups are distinguished in the same form(aluminium package). Licorice and Marshmallow have no significant smell and placebo will be the same color as the medicine  by using  allowed color. Also there is no significant difference between drug and placebo taste. The package  are separated  by mentioning the number. The list of numbers will be provided to the statistical consultant and then the data",3,60,Ahvaz University of Medical Sciences,Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of),"COVID 19. <br>Corona virus infection, unspecified;U07.1",FALSE,Yes,2020-04-09,2020-04-09,18 May 2020,NA,20200409,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,no limit,Both,Mehran Varnaseri Ghandali,NA,"Razi hospital, Felestin Ave, Amanieh Ave",Dr.varnaseri@gmail.com,+98 61 3333 7446,Ahvaz University of Medical Sciences,Inclusion criteria: Age =18 years<br>Laboratory polymerase chain reaction  (PCR) confirmed infection with COVID19.<br>Lung involvement confirmed with chest imaging<br>Hospitalized with: Fever (axillar or oral temperature = 38.0 °centigrade(C) or =38.6°centigrade tympanic or rectal) or   Respiratory rate >24/min Or Cough<br>Less than 8 days since illness onset<br>Willingness of study participant to accept randomization to any assigned treatment arm.<br>Acceptance of non-participation in another study before the 28th day of the study,"Exclusion criteria: Physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely.<br>Severe liver disease<br>Oxygen saturation=94%<br>Known allergic reaction to Marshmallow or Licorice<br>Severe renal impairment<br>Pregnant or breastfeeding women<br>Transfer to another non-study hospital within the next 72 hours<br>Receipt of any experimental treatment for COVID 19 within the 30 days prior to the time of the screening evaluation.<br>Angiotensin converting enzyme (ACE) inhibitor users<br>Hypertensive patients",Viral diagnostic test. Timepoint: The first day of the study and the end of the study (10th day). Method of measurement: Polymerase chain reaction.,NA,NA,NA,NA,NA,2020-04-09
0,1,NA,NA,"Randomized controlled Single blinded prospective multi centre clinical trial to
investigate the safety and efficacy of ZingiVir-H as an adjuvant therapy in hospitalized adults
diagnosed with coronavirus disease 2019 (COVID-19)","Intervention1: ZingiVir H: It is a poly herbomineral drug.Therapeutic dose:  <br>ONE tablet (500 mg) each consumed once in 3 hours Â±1 hour between 6 AM and 9 PM in a given day (6AM, 9AM, 12Noon, 3PM, 6PM, 9PM) for a minimum duration of 10 days to Maximum 15 days as per the clinical conditions and disease outcome.<br>Control Intervention1: not applicable: not applicable<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43168,Clinical research on safety and efficacy of ZingiVir-H as an add on therapy in COVID-19 patients.,CTRI,CTRI/2020/04/024883,2020-04-28,2020-04-29,FALSE,Interventional,"Other
  Method of generating randomization sequence:Other  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Outcome Assessor Blinded",Phase 4,112,Pankajakasthuri herbal research foundation,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,28-04-2020,29-04-2020,2 December 2020,NA,20200428,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,DrJHareendran Nair,NA,Pankajakasthuri Herbal research Foundation Pankajakasthuri Ayurveda Medical college Kattakkada Trivandrum Pankajakasthuri Ayurveda Medical college Kattakkada Trivandrum,drshan@pkhil.com,9188325339,Pankajakasthuri Herbal research Foundation,Inclusion criteria: 1. Patients of both sexes aged from 18 years to 60 years old. <br/ ><br>Willing and able to provide written informed consent prior to performing study <br/ ><br>procedures by the subject or legal guardian willing and able to provide written informed <br/ ><br>consent prior to performing study procedures <br/ ><br>3. Patients with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection <br/ ><br>confirmed by RT Polymerase chain reaction (RT-PCR) test between 1 and 120 Hours <br/ ><br>before randomization <br/ ><br>4. Currently hospitalized and requiring medical care for COVID-19 <br/ ><br>5. Peripheral capillary oxygen saturation (SpO2)  > 94% on room air at screening <br/ ><br>6. Radiographic evidence of pulmonary infiltrates,"Exclusion criteria: Candidates for the study will be excluded if ANY of the following criteria are present: <br/ ><br>1. Subject or Authorized Representative is unable to provide informed consent <br/ ><br>2. Subject is pregnant or breastfeeding ladies <br/ ><br>3. Subject is of childbearing potential and has a positive pregnancy test since admission to <br/ ><br>the hospital <br/ ><br>4. Subject is  < 18 years of age <br/ ><br>5. Subject has a known allergy to herbal compounds or ZingiVir-H or any components of <br/ ><br>the drug product <br/ ><br>6. Subject has had previous treatment with ZingiVir-H <br/ ><br>7. Body weight â?¥ 175 kg <br/ ><br>8. Intra-thoracic or intra-abdominal surgery within the 12 hours prior to consent, or ongoing <br/ ><br>impairment of hemostasis as a result of one of these procedures <br/ ><br>9. A history of head trauma, spinal trauma, or other acute trauma with an increased risk of <br/ ><br>bleeding. <br/ ><br>10. Cerebral Vascular Accident (CVA) or Intracerebral Arteriovenous Malformation (AVM), <br/ ><br>cerebral aneurysm, or mass lesions of the central nervous system or melena, <br/ ><br>hematemesis. <br/ ><br>11. Inability to take oral medication <br/ ><br>12. Prolonged QTc-interval in baseline ECG ( >500 ms) <br/ ><br>13. History of solid organ, allogeneic bone marrow, or stem cell transplantation. <br/ ><br>14. Severe renal failure characterized by chronic or acute need of hemodialysis, <br/ ><br>hemofiltration or peritoneal dialysis <br/ ><br>15. Need of anticoagulants, antiplatelet agents, antithrombotics and thrombolytics during the <br/ ><br>treatment period. <br/ ><br>16. Participation in another research study involving an investigational agent within 30 days prior to consent","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 15 [Time Frame: Day 15 from the day of study inclusion]. The odds ratio represents the odds of improvement in the ordinal scale between the treatment groups. The ordinal scale is an assessment of the clinical status at a given day. Each day, the worst score from the previous day will be recorded.  <br/ ><br>Timepoint: Baseline ,Day 7 and Day 15",NA,24/08/2020,NA,NA,NA,2020-04-28
0,1,NA,NA,Evaluation effects of DINVL herbal medicine on the recovery of patients with COVID - 19,"Intervention 1: Intervention group:??Dinvl drug,260 mg each time, 4 times a day for 7 days. Made by Health Medicine Chemistry Company. Intervention 2: Control group:  Routine  tablets is given daily for seven days.",http://en.irct.ir/trial/48001,Evaluation effect of Dinvl for Covid19 infection,IRCT,IRCT20200509047373N1,2020-05-23,2020-06-03,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: In this study, patients with admission conditions were divided into two groups. In addition to the usual treatment for coronavirus infection, the intervention group received Dinvl daily for 7consecutive days, but the control group received only routine treatment for corona infection , Randomization description: In this study, the random number table method is used for randomization.The randomization unit is also the individual.To read numbers, it is also from left to right.For concealment, the method of sequentially numbered, sealed, opaque envelopes is used, Blinding description: In this study, patients, the main researcher, the physician who visits patients daily for response to the treatment and examination of symptoms, and is responsible for collecting information, and the nursing staff are kept blind to the allocation of study groups.All pat",2-3,60,Health Medicine Chemistry Company,Iran (Islamic Republic of),"Pneumonia induced by covid19. <br>COVID-19, virus identified;U07.1",FALSE,Yes,2020-05-23,2020-06-03,15 June 2020,NA,20200523,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,no limit,no limit,Both,Ahmad Hosseinpour,NA,"No. 256, Alley 7, Peace Boulevard, Skills Square, Shiraz",ahosseinpour3@gmail.com,+98 71 3739 7910,Health Medicine Chemistry Company,Inclusion criteria: <br>                Patients  up18  years old hospitalized<br>                Patient with SpO2:85-89% on room air at admission (if correct with nasal O2 maximum 6 liter/min to SpO2>=90 )<br>                Patients with SpO2: 90-93% and RR>=30 clinical compatible<br>                patients with positive RT-PCR test or consistent HRCT to covid19<br>                pneumonia Sign the study participation form<br>,Exclusion criteria: <br>                Known sensitivity to plant compounds.<br>                Pregnant woman Lactating woman Patients with active peptic.<br>,"Time to clinical recovery. Timepoint: Control clinical signs daily until discharge from the hospital. Method of measurement: Fever control with thermometer, oxygen saturation control with pulsoximetry.",NA,NA,NA,NA,NA,2020-05-23
0,1,NA,NA,"Pulsed, inhaled nitric oxide (iNO) for the treatment of patients with mild or
moderate corona virus disease (COVID-19)",<br>Product Name: iNO<br>Pharmaceutical Form: Pressurised inhalation<br><br>,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002394-94,"Pulsed, inhaled nitric oxide (iNO) for the treatment of patients with mild or
moderate corona virus disease (COVID-19)",EUCTR,EUCTR2020-002394-94-BE,2020-06-04,2020-06-22,FALSE,Interventional clinical trial of medicinal product,"Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
","Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
",6,Dr. De Backer Wilfried BV,Belgium,"Corona virus disease <br>MedDRA version: 23.0
Level: LLT
Classification code 10084355
Term: COVID-19 virus test positive
System Organ Class: 100000004848
 <br>MedDRA version: 23.0
Level: LLT
Classification code 10084383
Term: Novel COVID-19-infected pneumonia
System Organ Class: 100000004862
 <br>MedDRA version: 23.0
Level: LLT
Classification code 10084401
Term: COVID-19 respiratory infection
System Organ Class: 100000004862
;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]",FALSE,Yes,04/06/2020,22/06/2020,7 September 2020,NA,20200604,12/3/2020 5:31:55 PM,EU Clinical Trials Register,Authorised,No,NA,NA,<br>Female: yes<br>Male: yes<br>,Clinical Trial Information Desk,NA,Lange Lozanastraat 142 (Regus 2nd floor),wilfried.debacker@outlook.com,0032476084883,Dr. De Backer Wilfried BV,Inclusion criteria: <br>1. Signed Informed Consent Form (and assent as appropriate) prior to<br>the initiation of any study mandated procedures or assessments.<br>2. At least 18 years old<br>3. Hospitalized patients with proven or high suspicion of SARS-CoV-2<br>infection and on supplemental oxygen >2 L/minute and = 10 L/minute<br>4. Suspected or proven pneumonia on chest imaging<br>5. Female patients of childbearing potential must have a negative pretreatment<br>pregnancy test (serum or urine). All female patients should<br>take adequate precaution to avoid pregnancy.<br>6. Willing and able to comply with treatment schedule and study<br>procedures.<br>Are the trial subjects under 18? no<br>Number of subjects for this age range: <br>F.1.2 Adults (18-64 years) yes<br>F.1.2.1 Number of subjects for this age range 3<br>F.1.3 Elderly (>=65 years) yes<br>F.1.3.1 Number of subjects for this age range 3<br>,"Exclusion criteria: <br>1. Participating in any other clinical trial of an experimental treatment<br>for COVID-19<br>2. Gas exchange and ventilation requiring the use of any continuous<br>positive airway pressure (CPAP), or any system of Non Invasive<br>Ventilation (NIV), with Positive End-Expiratory Pressure (PEEP) = 10<br>cmH2O prior to initiation of iNO<br>3. Pregnancy, or positive pregnancy test in a pre-dose examination<br>4. Open tracheostomy<br>5. Clinical contra-indication, as deemed by the attending physician including chronic lung disease<br>6. Use of a nitric oxide donor agent such as nitroglycerin or drugs<br>known to increase methemoglobin such as lidocaine, prilocaine,<br>benzocaine or dapsone at screening<br>7. Known history or clinical evidence of heart failure, left ventricular<br>dysfunction (LVEF < 40 %)<br>8. Patients reporting hemoptysis<br>","Main Objective: The objective of this study is to examine the utility of high resolution<br>computed tomography (HRCT) to measure changes in functional<br>pulmonary imaging parameters as a function of iNO administration using<br>the device INOpulse in relation to the corona virus disease. Changes<br>from baseling to at least 5 minutes of iNO and after 5 days using iNO 8 to<br>24 h/day.<br>Clinical evaluation of INOpulse for patients with COVID-19 using clinical<br>and imaging endpoints;Secondary Objective: Not applicable;Primary end point(s): Clinical evaluation of INOpulse for patients with COVID-19 using clinical<br>1. Death<br>2.  Hospitalized, requiring mechanical ventilation or ECMO<br>3. Hospitalized, requiring non-invasive ventilation or high flow oxygen<br>4. Hospitalized, requiring supplemental oxygen<br>5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)<br>6. Hospitalized, not requiring supplemental oxygen - not requiring ongoing medical care (COVID-19 related or otherwise)<br>7. Not hospitalized - limitation on activities and/or requiring home oxygen<br>8. Not hospitalized, no limitations on activities;Timepoint(s) of evaluation of this end point: Assessed at the start of iNOpulse treatment,during treatment, upon completion of treatment and at follow up (Day 28).",NA,NA,NA,NA,NA,2020-06-04
0,1,NA,NA,A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19),Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN;,http://www.chictr.org.cn/showproj.aspx?proj=50082,A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19),ChiCTR,ChiCTR2000030469,2020-03-02,2020-02-27,FALSE,Interventional study,Parallel,0,Control group:48;Experimental group:48;,Shanghai University of TCM,China,Novel Coronavirus Pneumonia (COVID-19),FALSE,No,2020-03-02,2020-02-27,9 March 2020,NA,20200302,12/3/2020 5:31:55 PM,ChiCTR,Recruiting,No,18,65,Both,Xiuming Song,NA,"528 Zhanghen Road, Pudong New Area District, Shanghai, China",Xiumingsong@sina.com,+86 13817525012,Shuguang Hospital Affiliated to Shanghai University of T.C.M.,"Inclusion criteria: 1. Real-time fluorescent RT-PCR detection of new coronavirus nucleic acid positive, or viral gene sequencing is highly homologous with known new coronavirus;<br>2. Confirmed as a novel coronavirus pneumonia common and severe patients, meets the diagnostic criteria of the ""novel coronavirus pneumonia diagnosis and treatment plan (trial implementation of the sixth edition)""<br>3. aged 18 to 65 years;<br>4. Learn about the significance of the study before the trial also the possible inconveniences and potential risk.","Exclusion criteria: 1. Patients with mild and critical novel coronavirus pneumonia;<br>2. Acute respiratory disease caused by non- novel coronavirus pneumonia;<br>3. Patients with diabetes and hypertension accompanied by severe primary immunodeficiency disease acquired immunodeficiency syndrome congenital respiratory malformation congenital heart disease pulmonary dysplasia and other diseases;<br>4. Patients with obvious abnormal heart, liver and kidney disease or serious other system diseases such as digestive system urogenital system blood system hemorrhagic disease central nervous system psychiatric diseases in acute stage, and endocrine and metabolic diseases;<br>5. People who are known to be allergic to the ingredients in the research drug, or patients with allergies; <br>6. Women who are breastfeeding, pregnant, or have a positive urine pregnancy test;<br>7. Patients who are participating in other clinical trials or patients who have participated in other drug clinical trials within 1 month;<br>8. Researchers find the patient inappropriate to be involved in the trial.",fever clearance time;Effective rate of TCM symptoms;,NA,NA,NA,NA,NA,2020-03-02
0,1,NA,NA,Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19),Group A:traditional Chinese medicine treatment;Group B:Lopinavir / Ritonavir;Group C:traditional Chinese medicine treatment and Lopinavir / Ritonavir;,http://www.chictr.org.cn/showproj.aspx?proj=48824,Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19),ChiCTR,ChiCTR2000029400,2020-01-29,2020-01-29,FALSE,Interventional study,Non randomized control,0,Group A:20;Group B:20;Group C:20;,China Academy of Chinese Medical Sciences,China,novel coronavirus pneumonia (COVID-19),FALSE,Yes,2020-01-29,2020-01-29,17 February 2020,NA,20200129,12/3/2020 5:31:55 PM,ChiCTR,Recruiting,No,18,NA,Both,Huang Luqi,NA,"16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China",huangluqi01@126.com,+86 010-64089801,China Academy of Chinese Medical Sciences,"Inclusion criteria: 1) Comply with the diagnostic criteria for pneumonia caused by novel coronavirus infection in the ""Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 4)"";<br>2) Agree to participate in the study and the patient or legal guardian signs the informed consent form.","Exclusion criteria: 1) Patients with particularly severe pneumonia caused by novel coronavirus infection.<br>2) Patients whose initial onset time exceeds 5 days.<br>3) Patients with severe primary respiratory disease.<br>4) It is difficult to administer to patients by oral or nasal feeding.<br>5) Pregnant women, as well as patients with other malignancies such as malignant tumors, mental illnesses, and patients who are not considered suitable for study.",the rate of remission;,NA,NA,NA,NA,NA,2020-01-29
0,1,NA,NA,Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia,1:7/5000   Low molecular weight heparin therapy;2:The mechanical prevention;,http://www.chictr.org.cn/showproj.aspx?proj=51265,Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19),ChiCTR,ChiCTR2000030946,2020-03-19,2020-02-10,FALSE,Interventional study,Non randomized control,4,1:80;2:40;,The First Affiliated Hospital of Guangzhou Medical University,China,Novel Coronavirus Pneumonia (COVID-19),FALSE,No,2020-03-19,2020-02-10,23 March 2020,NA,20200319,12/3/2020 5:31:55 PM,ChiCTR,Recruiting,No,18,80,Both,Chunli Liu,NA,"151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China",chunli@gird.cn,+86 13560158649,The First Affiliated Hospital of Guangzhou Medical University,"Inclusion criteria: 1. Patients diagnosed with new coronavirus pneumonia and in need of hospitalization: they meet the diagnostic criteria of the diagnosis and treatment program for new coronavirus pneumonia (trial fifth edition) issued by the national health commission;<br>2. Pneumonia with novel coronavirus confirmed by aetiological nucleic acid test;<br>3. Aged 18 to 80 years;<br>4. Sign the informed consent;<br>5. VTE score was greater than or equal to 4, and there were no higher blood risk factors.","Exclusion criteria: 1. Pregnant women or lactating women;<br>2. Severe liver function damage (child-pugh grade C);<br>3. Severe renal impairment (Ccr<=15ml/min);<br>4. Have any coexisting medical conditions or diseases that the investigator determines may impair the conduct of the study;<br>5. Social and mental disability, no legal capacity/restricted capacity;<br>6. Refuse to sign the informed consent;<br>7. VTE score <4;<br>8. Higher blood risk factors.",The biochemical indicators;,NA,NA,NA,NA,NA,2020-03-19
0,1,NA,NA,Evaluation of Efficacy and Safety of Ayurveda Intervention (Ayush -64) in the management of COVID-19 infection (Asymptomatic &Mild to Moderate symptoms)- An open label single arm prospective clinical trial,Intervention1: Ayush 64: Dose:		2 capsules (500 mg each) thrice  daily (2-2-2)<br>Dosage form: 		Tablets <br>Route of Administration:	Oral<br>Time of Administration:	Thrice a day after food<br>Anupana:		Warm Water 	<br>Duration of therapy:	14 days<br><br>Control Intervention1: Not applicable: Not applicable<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44033,Evaluation of Efficacy and Safety of Ayurveda Intervention (Ayush -64) in the management of COVID-19 infection (Asymptomatic &Mild to Moderate symptoms,CTRI,CTRI/2020/05/025338,2020-05-24,2020-06-02,FALSE,Interventional,"Single Arm Trial
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable",Phase 2/ Phase 3,40,Central Council For Research in Ayurvedic Sciences,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,24-05-2020,02-06-2020,2 December 2020,NA,20200524,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Shivshankar Rajput,NA,"IPD Building First Floor
Central Ayurved Research Institute for cardiovascular Diseases, Road No. 66 Punjabi bagh west , New Delhi",drbabitayadav@gmail.com,9910171143,CCRAS,"Inclusion criteria: 1.Mild to moderate cases registered in Ayurved and Unani Tibbia College and Hospital Designated as COVID Health Center above the age of 18 years, with COVID 2019 (Confirmed by RT-PCR) quarantined at identified hospital setup. <br/ ><br>2.Participants who can take medicines orally <br/ ><br>3.Patients willing to provide signed informed consent","Exclusion criteria: 1.Cases of severe vomiting which would make oral administration of medicine difficult. <br/ ><br>2.Cases of respiratory failure and requiring mechanical ventilation. <br/ ><br>3.Alanine Transaminase (ALT) or Aspartate Transaminase (AST)  > 2 times the upper limit of normal. <br/ ><br>4.Patients with COVID 19 in critical condition or ARDS or NIAD 8 â??point ordinal score 2 Hospitalized, on invasive mechanical Ventilation or extra corporeal membrane oxygenation <br/ ><br>5.Pregnant or lactating women <br/ ><br>6.Any other condition, which as per the investigator would jeopardize the outcome of the trial.",a)	Mean time (days) for clinical recovery as per clinical recovery criteria defined below.   <br/ ><br>b)	Number of patients showing â??clinical recoveryâ??.  <br/ ><br>Timepoint: a)	Mean time (days) for clinical recovery as per clinical recovery criteria defined below. [Time frame: Daily]  <br/ ><br>b)	Number of patients showing â??clinical recoveryâ??. [Time frame: Daily],NA,01/09/2020,NA,NA,NA,2020-05-24
0,1,NA,NA,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Dietary Supplement: Ascorbic Acid;Dietary Supplement: Zinc Gluconate;Dietary Supplement: Ascorbic Acid and Zinc Gluconate;Other: Standard of Care,https://clinicaltrials.gov/show/NCT04342728,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,CT.gov,NCT04342728,2020-04-08,2020-04-08,FALSE,Interventional,Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).,N/A,520,The Cleveland Clinic,United States,COVID;Corona Virus Infection,FALSE,Yes,08/04/2020,"April 8, 2020",24 August 2020,COVIDAtoZ,20200408,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,;,"Milind Desai, M. D.;Suma Thomas",NA,;,;,The Cleveland Clinic;The Cleveland Clinic,"<br>        Inclusion Criteria:<br><br>          -  Outpatients = 18 years presenting to Cleveland Clinic Health System in Ohio and<br>             Florida who test positive for COVID-19 having any of the following symptoms<br><br>               1. Fever or chills<br><br>               2. Shortness of breath or difficulty breathing<br><br>               3. Cough<br><br>               4. Fatigue<br><br>               5. Muscle or body Aches<br><br>               6. Headache<br><br>               7. New loss of taste<br><br>               8. New loss of smell<br><br>               9. Congestion or runny nose<br><br>              10. Nausea<br><br>              11. Vomiting<br><br>              12. Diarrhea<br><br>        Women of child bearing potential:<br><br>          1. have had a menstrual period within the past 30 days, or<br><br>          2. have had previous sterilization, or<br><br>          3. are perimenopausal (less than 1 year) who have a negative pregnancy test, or<br><br>          4. women of childbearing potential who do not meet the above and have a negative<br>             pregnancy test.<br><br>        Exclusion Criteria:<br><br>          -  Patients who are found to be positive during hospitalization<br><br>          -  Patients who reside outside Ohio or Florida.<br><br>          -  Pregnant women:<br><br>               1. Current known pregnancy<br><br>               2. Positive pregnancy test (women of child bearing potential who have not had<br>                  previous sterilization as defined as hysterectomy or tubal ligation)<br><br>          -  Women of childbearing potential who do not meet the above criteria, last menstrual<br>             period greater than 30 days and have a positive pregnancy test.<br><br>          -  Lactating Women<br><br>          -  End stage kidney disease<br><br>          -  Advanced liver disease awaiting transplant<br><br>          -  History of Calcium Oxalate kidney stones.<br>",NA,Symptom Reduction,NA,NA,NA,NA,NA,2020-04-08
0,1,NA,NA,An Open Label Single arm Clinical Trial on the effectiveness of Ayurveda interventions in the management of Hospitalized Mild to moderate COVID-19 patients.,"Intervention1: Ayurveda Drug intervention for 10 days: Vyaghryadi kwatha <br>	50  ml twice a day<br><br>Samshamani Vati <br>	2 tablets 500 mg each twice daily<br>Ashwagandha (Withania somniferum)<br>	2gm in powdered form, once daily with warm water.<br>Rasona Kalka 	1gm once daily with warm water.<br><br><br><br><br>Intervention2: biochemical markers: Haemogram, Platelet count, TLC, DLC, Haemoglobin and ESR.<br>Blood Sugar level<br>C-Reactive Protein<br>Liver Function Test<br>Kidney Function Test<br>Ferritin<br>D-Dimer<br>LDH<br>Selected Cytokines: Gamma Interferon, Tumor Necrosis factor (Alpha and Beta), Interleukin-6.<br>Nasal and Throat swab for specific test for COVID 19 based on RT-PCR.<br><br>Control Intervention1: Not applicalble: Not applicable<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45909,Ayurvedic intervention in COVID-19 patients,CTRI,CTRI/2020/07/026922,2020-07-30,2020-08-04,FALSE,Interventional,"Single Arm Trial
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable",N/A,30,State plan management Unit National Health Mission Uttar Pradesh,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,30-07-2020,04-08-2020,2 December 2020,NA,20200730,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Adil Rais,NA,"Panchakarma Unit
room no 114
 LDA Kanpur Road
Lucknow",adil.rais13@gmail.com,7060272769,Lokbandhu Rajnarayan Combined Hospital,Inclusion criteria: Mild to Moderate COVID-19 Positive cases. <br/ ><br>Patients with mild co-morbidities. <br/ ><br>Patients willing to give informed consent.,Exclusion criteria: Severe type of COVID-19 Positive cases. <br/ ><br>Patients with severe co-morbidities. <br/ ><br>Patients with Severe Difficulty in breathing. <br/ ><br>Patients willing to give informed consent.,<br/ ><br>To assess role of Ayurvedic Drugs on the immunological markers in Covid 19 patients <br/ ><br> <br/ ><br>Timepoint: 10 days,NA,NA,NA,NA,NA,2020-07-30
0,1,NA,NA,"Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure",Drug: INO-4800;Device: CELLECTRA® 2000;Drug: Placebo;Device: CELLECTRA® 2000,https://clinicaltrials.gov/show/NCT04642638,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure",CT.gov,NCT04642638,2020-11-23,2020-11-01,TRUE,Interventional,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Phase 2/Phase 3,6578,Inovio Pharmaceuticals,United States,Coronavirus Infection;Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2);COVID-19 Disease,FALSE,Yes,23/11/2020,November 2020,30 November 2020,NA,20201123,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,;,"Mammen P. Mammen Jr, M.D., FACP, FIDSA;Inovio Call Center",NA,;clinical.trials@inovio.com,;(267) 440-4237,Inovio Pharmaceuticals;,"<br>        Key Inclusion Criteria:<br><br>          -  Working or residing in an environment with high risk of exposure to SARS-CoV-2 for<br>             whom exposure may be relatively prolonged or for whom personal protective equipment<br>             (PPE) may be inconsistently used, especially in confined settings.<br><br>          -  Screening laboratory results within normal limits for testing laboratory or are deemed<br>             not clinically significant by the Investigator.<br><br>          -  Be post-menopausal or be surgically sterile or have a partner who is sterile or use<br>             medically effective contraception with a failure rate of < 1% per year when used<br>             consistently and correctly from Screening until 3 months following last dose.<br><br>        Key Exclusion Criteria:<br><br>          -  Acute febrile illness with temperature higher than 100.4°F (38.0°C) or acute onset of<br>             upper or lower respiratory tract symptoms (e.g., cough, shortness of breath, sore<br>             throat).<br><br>          -  Positive serologic or molecular (Reverse transcription polymerase chain reaction<br>             (RT-PCR)) test for SARS-CoV-2 at Screening.<br><br>          -  Pregnant or breastfeeding or intending to become pregnant or intending to father<br>             children within the projected duration of the trial starting from the Screening visit<br>             until 3 months following the last dose.<br><br>          -  Known history of uncontrolled HIV based on a CD4 count less than 200 cells per cubic<br>             millimeter (/mm^3) or a detectable viral load within the past 3 months.<br><br>          -  Is currently participating or has participated in a study with an investigational<br>             product within 30 days preceding Day 0.<br><br>          -  Previous receipt of an investigational vaccine for prevention or treatment of<br>             COVID-19, middle east respiratory syndrome (MERS), or severe acute respiratory<br>             syndrome (SARS) (documented receipt of placebo in previous trial would be permissible<br>             for trial eligibility).<br><br>          -  Respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease) requiring<br>             significant changes in therapy or hospitalization for worsening disease during the 6<br>             weeks prior to enrolment.<br><br>          -  Immunosuppression as a result of underlying illness or treatment.<br><br>          -  Lack of acceptable sites available for ID injection and EP.<br><br>          -  Blood donation or transfusion within 1 month prior to Day 0.<br><br>          -  Reported alcohol or substance abuse or dependence, or illicit drug use (excluding<br>             marijuana use).<br><br>          -  Any illness or condition that in the opinion of the investigator may affect the safety<br>             of the participant or the evaluation of any study endpoint.<br>",NA,Phase 2: Change From Baseline in Antigen-specific Cellular Immune Response Measured by Interferon-gamma (IFN-?) Enzyme-linked Immunospot (ELISpot) Assay;Phase 2: Change From Baseline in Neutralizing Antibody Response Measured by a Pseudovirus-based Neutralization Assay;Phase 3: Percentage of Participants With Virologically-confirmed COVID-19 Disease,NA,NA,NA,NA,NA,2020-11-23
1,0,NA,NA,"Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)",Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg;Drug: Drug: Standard treatment Standard treatment,https://clinicaltrials.gov/show/NCT04578236,"Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)",CT.gov,NCT04578236,2020-10-04,2020-11-01,TRUE,Interventional,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,360,Kafrelsheikh University,NA,Covid19,FALSE,Yes,04/10/2020,November 2020,2 November 2020,NA,20201004,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,80 Years,All,;,"Mahmoud Elkazzaz, B.Sc in Biochemistry;Mahmoud Elkazzaz, B.Sc in Biochemistry",NA,;mahmoudramadan2051@yahoo.com,;00201090302015,"Faculty of Science, Damietta University;","<br>        Inclusion Criteria:<br><br>        Adult SARI patients with 2019-ncov infection confirmed by PCR; Absolute value of<br>        lymphocytes < 0. 6x 109/L; Severe respiratory failure within 48 hours and requires<br>        admission to ICU. (severe respiratory failure was defined as PaO2/FiO2 < 200 mmHg and was<br>        supported by positive pressure mechanical ventilation (including non-invasive and invasive<br>        mechanical ventilation, PEEP>=5cmH2O))<br><br>        Exclusion Criteria:<br><br>        Age < 18 Pregnant Allergic to experimental drugs and patients have the following<br>        conditions:<br><br>          -  Hypercholesterolemia<br><br>          -  Hypertriglyceridemia<br><br>          -  Liver disease<br><br>          -  Renal disease<br><br>          -  Sjögren syndrome<br><br>          -  Pregnancy<br><br>          -  Lactation<br><br>          -  Depressive disorder<br><br>          -  Body mass index less than 18 points or higher than 25 points<br><br>          -  Contraindications for hormonal contraception or intrauterine device.<br><br>          -  Autoimmune diseases A history of organ, bone marrow or hematopoietic stem cell<br>             transplantation<br><br>          -  Patients receiving anti-hcv treatment<br><br>          -  Permanent blindness in one eye<br><br>          -  History of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of<br>             retinal detachment or eye surgery<br><br>          -  History of ACE-inhibitor allergy<br><br>          -  History of angio-oedema<br><br>          -  Co-infection with another respiratory pathogen which could be responsible of pneumonia<br><br>          -  Hypersensitivity to captopril, to any other angiotensin converting enzyme inhibitor or<br>             any of the excipients of the specialty used<br><br>          -  Shock requiring vasopressor infusion<br><br>          -  Patient on state medical ai<br><br>          -  The competent physician considered it inappropriate to participate in the study<br>",NA,lung injury score,NA,NA,NA,NA,NA,2020-10-04
1,0,NA,NA,"The efficacy and safety of Siddha Treatment in Symptomatic Participants with novel coronavirus infectious disease (COVID-19): A Multicenter, Randomized, Open-Label, Active-controlled Randomised Clinical Trial","<br>                The study consists of the following periods/assessments for participants in both the intervention and control arms.<br>                1. Screening period: -3 to -1 days. This will involve taking informed consent, assessing eligibility and comorbidity (e.g. Hypertension, Diabetes, Cardiovascular disease, etc.) through taking a medical and surgical history, smoking history, previous medication history, demographic history, physical examination, serology, 12-lead ECG, and vital signs.<br>                2. Treatment period: 0 to 14 days<br>                3. Follow-up period: 0 to 28 days. Patients will attend five study assessments at 0 (baseline assessment), 2, 8, 15 and 29 days. If nasal swabs taken at 15 days are negative participants will be invited to return 24 h later on day 16 for a second swab.<br>                4. Safety Follow-up assessment: 28 days after the last dose of the Siddha treatment was received in the event of early termination<br><br>                The patients selected for participation will be assigned randomly to one of the two treatment groups, Siddha treatment regimen + Standard of Care, or Standard of Care only, in 1:1 ratio balancing the stratification factor of co-morbidity status.<br><br>                The stratified permuted block randomization design will be used to randomize the patients in 1:1 ratio among the two treatment groups.<br><br>                Siddha treatment regimen + Standard of care will involve Siddha treatment with Kabasura kudineer and Brammanandha bairavam where indicated in addition to standard care as per local/government guidance. Kabasura kudineer will be given in the dose of 60 ml, twice a day for 7 days taken 90 minutes before food. Brammanandha bairavam will be given in the dose of 100 mg, three times a day for 7 days, ta",http://isrctn.com/ISRCTN13311119,START (Siddha Treatment Accelerating Recovery from SARS-CoV-2 Test) trial of Siddha treatment for patients with novel coronavirus infectious disease (COVID-19),ISRCTN,ISRCTN13311119,2020-04-24,2020-04-30,FALSE,Interventional,"A Multicenter, Randomized, Open-Label, Active-controlled Randomised Clinical Trial (Treatment)",Phase II,116,Eminentlabs GmbH,India,COVID-19 (SARS-CoV-2 infection) <br>Respiratory <br>COVID-19 (SARS-CoV-2 infection),FALSE,Yes,24/04/2020,30/04/2020,4 May 2020,NA,20200424,12/3/2020 5:31:55 PM,ISRCTN,Recruiting,No,NA,NA,Both,NA,NA,NA,NA,NA,NA,"Inclusion criteria: <br>                1. Aged between 18 and 75 years<br>                2. Laboratory-confirmed COVID-19<br>                3. Presence of any 2 symptoms of COVID-19: fever, cough, sore throat, myalgia, fatigue, headache or dyspnea<br>                4. Not currently hospitalized or under immediate consideration for hospitalization. Hospitalization is defined as admission where patients require parenteral/Intravenous (IV) medications or IV fluids, oxygen or ventilatory support in hospital. Isolation or quarantine inside the hospital premises alone will not be considered as hospitalization.<br>                5. Meets clinical features of the following grades of severity:<br>                5.1. Suspected/confirmed cases in COVID Care Centres, clinically assigned as mild and very mild, presenting with fever and/or upper respiratory tract illness<br>                5.2. Suspected/confirmed cases in Dedicated COVID Health Centres, clinically assigned as moderate, presenting with  pneumonia with no signs of severe disease (Respiratory Rate 15 to 30 breaths/minute, SpO2 90%-94%)<br>                6. Willing to practice contraception during the entire study treatment period and for 3 months after the last treatment of IMP is administered, using either double barrier contraception or sexual abstinence (when this is in line with the preferred and usual lifestyle of the participant)<br>                7. Patients or their legal representatives have personally signed and dated signed the informed consent form (ICF) before completing any study-related procedure, which means before any assessment or evaluation that would not have formed a part of his normal medical care<br>                8. Willing to adhere and comply with the protocol-related procedures<br>                9. Willing to take Siddha drug regimen for COVID-19 infection<br>                10. Willing to not participate in other clinical studies within 30 days after the last administration from the first administration of the study drug<br>","Exclusion criteria: <br>                1. Viral pneumonia with cause other than SARS-CoV-2<br>                2. Severe or critical COVID-19 infection<br>                3. Taken antibiotics/antivirals in the past 1 week<br>                4. History of Asthma, COPD or any other chronic lung disease<br>                5. Active malignancy<br>                6. Received organ transplantation in the past 6 months or planning surgery<br>                7. Unable to take food or drugs orally<br>                8. Malabsorption or GI abnormalities which may affect drug absorption<br>                9. Severe underlying diseases affecting survival, including but not limited to: blood diseases, dyscrasia, active bleeding, severe malnutrition, etc.<br>                10. Subjects who are pregnant or lactating, have a pregnancy plan (including plans for sperm donation or egg donation), or who may fail to take effective contraceptive measures within the next 6 months<br>                11. Allergic constitution, or known allergy to investigational products<br>                12. Testing positive for HIV, Hepatitis B and Hepatitis C at screening<br>                13. Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper limit of normal.<br>                14. Requiring Extracorporeal Life Support Program (ECLS), i.e. Extracorporeal Membrane Oxygenation (ECMO), Extracorporeal carbon dioxide removal (ECCO2R) or Registered Respiratory Therapist (RRT)<br>                15. Life expectancy < 48 h<br>",Proportion of patients confirmed as negative for COVID-19 in 2 consecutive throat/nasal swabs (taken 24 hours apart) at 15 and 16 days,NA,26/06/2020,NA,NA,NA,2020-04-24
0,1,NA,NA,A comparison of Elderberry (Sambucus nigra) extract syrup and placebo against COVID-19 symptoms in outpatients and home quarantined patients: A randomized double-blind clinical trial,"Intervention 1: Intervention group:The patients will receive 10 ml of elderberry extract syrup 3 times daily (2.6 g of elderberry extract per day equivalent to 15.76 g of fresh elderberries) beside the standard treatment regimen for COVID-19 according to the Ministry of Health protocol. This treatment will continue for 2 weeks. The syrup is formulated according to the United States Pharmacopoeia description. This syrup is preservative-free and remains stable for up to 1 month. The syrups will be prepared freshly at the School of Pharmacy, Mashhad University of Medical Sciences. Intervention 2: Control group: The patients will receive the placebo syrup beside the standard treatment regimen for COVID-19 according to the Ministry of Health protocol with the same order as the intervention group.The placebo consists of USP syrup formula with food-grade coloring agents with the same shape and size containers as the elderberry syrup. This syrup is preservative-free and will be prepared freshly at the School of Pharmacy, Mashhad University of Medical Sciences.",http://en.irct.ir/trial/46958,The effect of elderberry syrup against COVID-19 symptoms,IRCT,IRCT20200406046965N1,2020-04-12,2020-04-20,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization happens at three stages: 
1- Random sequence generation: Simple or limited randomization will be performed based on the table of random numbers.
2- Allocation concealment: This step will be performed in the form of coded boxes (numbered drug containers) with a random sequence. In this method, a number of boxes with the same shape and size are numbered based on random sequences, containing either treatment drug or placebo with a completely similar appearance. 
3- Execution of random allocation process: 
A: To identify the person who creates the random sequence 
B: A person who evaluates and registers researchers in terms of inclusion and exclusion criteria.
C: The person who has assigned the participants to the groups: Infectious diseases specialist who creates a random sequence, does not interfere in other stages of randomization, i",2,40,Mashhad University of Medical Sciences,Iran (Islamic Republic of),"COVID-19 disease. <br>COVID-19, virus identified;U07.1",FALSE,Yes,2020-04-12,2020-04-20,18 May 2020,NA,20200412,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,65 years,Both,Seyed Ahmad Emami,NA,"School of Pharmacy, University Campus, VakilAbad boulvard",emamia@mums.ac.ir,+98 51 3180 1267,Mashhad University of Medical Sciences,"Inclusion criteria: A definitive diagnosis of COVID-19 infection based on laboratory confirmation (lymphocytopenia, increased quantitative CRP, chest X-ray results) and clinical symptoms of patients including fever, coughs and myalgia<br>Outpatients and home quarantined patients","Exclusion criteria: Hospitalization<br>Age> 65 y and <18 y<br>Patients with catheter<br>Patients receiving chemotherapy drugs, corticosteroids and theophylline<br>Autoimmunity<br>Gastrointestinal diseases<br>Migraine<br>Diabetes<br>Hypokalemia<br>Myalgia<br>Respiratory diseases<br>Smoking<br>Pregnancy and breast feeding","Fever. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Thermometer.;Shortness of breath. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Autosaturation device, Counting the number of breaths in 1 minute.;Coughs. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Patient follow up.;Myalgia. Timepoint: Days 3, 7 and 14 after the intervention beginning. Method of measurement: Patient follow up.",NA,NA,NA,NA,NA,2020-04-12
0,1,NA,NA,"The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Pakistan",Drug: Honey;Drug: Nigella Sativa / Black Cumin;Drug: Placebos,https://clinicaltrials.gov/show/NCT04347382,Honey & Nigella Sativa Trial Against COVID-19,CT.gov,NCT04347382,2020-04-11,2020-04-30,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Care Provider, Investigator, Outcomes Assessor).",Phase 3,313,Sohaib Ashraf,Pakistan,Coronavirus Infection;Sars-CoV2,FALSE,Yes,11/04/2020,"April 30, 2020",24 November 2020,HNS-COVID-PK,20200411,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,; ; ; ;,"Shoaib Ashraf, PhD;Muhammad Ashraf, DVM, PhD;Sohaib Ashraf, MBBS;Muhammad Ahmad Imran, MBBS;Ayesha Hamayun, MBBS, PhD",NA,;;;;,;;;;,"Massachusetts General Hospital, Harvard Medical School, USA;University Of Veterinary & Animal Sciences, Lahore;Federal Post-Graduate Medical Institute, Lahore;Shaikh Zayed Hospital, Lahore;Shaikh Khalifa Bin Zayed Al-Nahyan Medical & Dental College, Lahore","<br>        Inclusion Criteria:<br><br>          -  Confirmed SARS-CoV-2 (COVID-19) infection by a positive test result with SSC-2 score><br>             5<br><br>          -  Patients admitted in Corona centers<br><br>        Exclusion Criteria:<br><br>          -  Participants not giving consent.<br><br>          -  Pregnant and lactating females.<br><br>          -  History of allergy to any drug being administered in this study<br><br>          -  Severely terminally ill patients<br><br>          -  Patients on Nil Per Oral<br>",NA,Days required to get a positive COVID-19 PCR to negative;Severity of symptoms progression;Duration of Hospital Saty;30 day mortality;Clinical Grade Status;Fever,NA,NA,NA,NA,NA,2020-04-11
0,1,NA,NA,The Effectiveness of Combined Extract of 8 Medicinal Plants on the Control of Mild to Moderate Symptoms of Covid-19 Disease: A Clinical Trial,"Intervention 1: Control group: Uses common medicines and boiled water. Intervention 2: Intervention group: Due to the fact that the resulting extract is prepared at a temperature of less than 100. C (70) C) and is in fact a kind of drink, the amount of consumption of the rules of consumption of the drink is followed by a slight change in consumption time. Typically, herbal teas are prescribed 3 times a day and 100 cc each time. In this study, people with the disease are prescribed 5 cc of the extract at intervals of 30 minutes. The total amount of extracted in 24 hours for each patient is 240 cc.",http://en.irct.ir/trial/47987,Combined effects of Extracts on  Covid-19,IRCT,IRCT20200508047345N1,2020-06-14,2020-06-21,FALSE,interventional,"Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Other, Purpose: Treatment.",N/A,100,Shiraz University of Medical Sciences,Iran (Islamic Republic of),Covid-19. <br>COVID-19;U07.1,FALSE,Yes,2020-06-14,2020-06-21,13 July 2020,NA,20200614,12/3/2020 5:31:55 PM,IRCT,Not Recruiting,No,no limit,no limit,Both,Mohammad Jamal Saharkhiz,NA,8 Km Nasr Blvd.,saharkhiz@shirazu.ac.ir,+98 71 3723 0235,Shiraz University of Medical Sciences,"Inclusion criteria: Positive corona testing or confirmation of symptoms such as fever, muscle and bone pain, cough and sore throat<br>In the paraclinical study of these patients, platelet counts, white blood cell counts, as well as ESR and CRP levels were significantly increased<br>In the blood gas test, the saturation of O2 is less than 93%","Exclusion criteria: Patients who have a history of allergies to herbal medicines or have insufficiency and underlying liver, kidney, heart and vascular diseases<br>Patients with diabetes or other endocrine diseases<br>Normally, pregnant and lactating mothers also have insufficient evidence of the safety of herbal medicine due to the lack of evidence<br>Patients who are unable to swallow or are NPO<br>Patients under mechanical ventilation<br>People who are constantly under the control and treatment of neuroleptic drugs","Percentage of people with normal breathing (oxygen saturation value). Timepoint: Measurement of oxigenesis at the beginning of the study and 1, 2, 3, 4 and 5 days after starting to use the medicinal extract. Method of measurement: Pulse Oximeter instrument.",NA,NA,NA,NA,NA,2020-06-14
1,0,NA,NA,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm; a Retrospective Propensity Matched Control Study,Procedure: Therapeutic Plasma Exchange,https://clinicaltrials.gov/show/NCT04485169,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,CT.gov,NCT04485169,2020-07-21,2020-04-01,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,N/A,280,UNICEF,Pakistan,COVID-19;Cytokine Release Syndrome,FALSE,Yes,21/07/2020,"April 1, 2020",5 October 2020,Plex,20200721,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,80 Years,All,NA,"Imran m Fazal, FCPS",NA,NA,NA,Pak Emirates Military Hospital (PEMH) Rawalpindi,"<br>        Inclusion Criteria:<br><br>          -  COVID-19 diagnosed by Polymerase Chain Reaction (PCR) positivity for SARS-CoV2<br><br>          -  CRS at presentation or developing during hospitalization<br><br>          -  10-80 years age and both genders<br><br>          -  hospital admission<br><br>          -  At least 1 completed session of plasma-exchange in patients included in TPE arm<br><br>          -  No other novel therapy administered.<br><br>        Exclusion criteria were:<br><br>          -  Death within 48 hours of admission<br><br>          -  severe septic shock at time of admission<br><br>          -  Congestive cardiac failure (EF<20%) (4)<br><br>          -  Those receiving immunotherapy, Anti-thymocyte globulin or hematopoietic stem cell<br>             transplant in recent past<br><br>          -  Patients of hematological or solid organ malignancies<br><br>          -  patients receiving other investigational drugs including Tocilizumab, Convalescent<br>             plasma, Remdesivir, or Mesenchymal stem cells.<br>",NA,Survival,NA,NA,NA,NA,NA,2020-07-21
0,1,NA,NA,A randomized open labeled clinical study to compare the effectiveness of Kabasura kudineer and Vitamin-C Zinc supplementation in the management of asymptomatic SARS-CoV-2 patients,"Intervention1: Kabasura kudineer: Siddha medicine<br>30 â?? 60 ml twice daily orally<br>Control Intervention1: Zinc and Vitamin C: Zinc -100 mg, Vit C â?? 60000 IU twice daily orally<br>",http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44684,To observe the effect of Siddha formulation Kabasura kudineer in COVID 19 patients,CTRI,CTRI/2020/06/025874,2020-06-15,2020-06-24,FALSE,Interventional,"Randomized, Parallel Group Trial
  Method of generating randomization sequence:Coin toss, Lottery, toss of dice, shuffling cards etc  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label",Phase 2,60,Dean Government Theni Medical College,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,15-06-2020,24-06-2020,2 December 2020,NA,20200615,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr C Anbarasi,NA,"Arignar Anna Hospital Campus
Arumbakkam
Chennai Arignar Anna Hospital Campus
Arumbakkam
Chennai",drsankararaj@gmail.com,9965897075,Government Theni Medical College and Hospital,Inclusion criteria: 1.Laboratory confirmed COVID-19 without symptoms <br/ ><br>2.Consenting to participate in the study and sign the informed consent,"Exclusion criteria: 1.Patient with co morbid conditions like DM, HT and BA. <br/ ><br>2.Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID-19. <br/ ><br>3.Pregnant and mothers those who have a pregnancy plan. <br/ ><br>4.Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, etc., which the researchers consider unsuitable for participation in the study. <br/ ><br>5.People who have been allergic to Siddha medicine or intolerant to taking medicine. <br/ ><br>6.Patients participating in other COVID-19 clinical trials. <br/ ><br>","1.Reduction in incidence of clinical symptoms like fever, cough and breathlessness. <br/ ><br>2.Negative conversion of SARS-CoV-2 by 14 days <br/ ><br>3.Reduction in Viral load of SARS-CoV-2 at the end of treatment (0, 7, 14 days) <br/ ><br>4.Examine the levels of immune markers and inflammatory markers (IgG, IgM, IgA, Th1 (TNF-Alfa, IFN-gamma, IL2) Th2 (IL6, IL10) at the end of treatment (0, 7, 14 days) <br/ ><br>Timepoint: 14 days",NA,NA,NA,NA,NA,2020-06-15
1,0,NA,NA,Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population,Community exposure TCM intervention group:TCM intervention;Community exposure control group:Placebo;Hospital exposure TCM intervention group:TCM intervention;Hospital exposure control group:Placebo;Community suspected TCM intervention group:TCM intervention;Community suspected control group:Placebo;Hospital suspected TCM intervention group:TCM intervention;Hospital suspected control group:Placebo;,http://www.chictr.org.cn/showproj.aspx?proj=48827,Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population,ChiCTR,ChiCTR2000029435,2020-02-01,2020-02-01,FALSE,Interventional study,Parallel,0,Community exposure TCM intervention group:20;Community exposure control group:20;Hospital exposure TCM intervention group:20;Hospital exposure control group:20;Community suspected TCM intervention group:20;Community suspected control group:20;Hospital su,Wuhan 1st Hospital,China,novel coronavirus pneumonia (COVID-19),FALSE,Yes,2020-02-01,2020-02-01,17 February 2020,NA,20200201,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,18,60,Both,Wei Li,NA,"215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China",whsdyyykjc@126.com,+86 13163283819,Wuhan 1st Hospital,"Inclusion criteria: 1. aged 18 to 60 years<br>2. to be confirmed with a exposure history of diagnosed population within last 14 days;<br>3. with fever, positive results of blood routine examination and positive findings in CT examination, any two in three items met.","Exclusion criteria: 1. Pregnancy or lactation;<br>2. Previous serious chronic basic diseases;<br>3. Previous allergy to traditional Chinese medicine;<br>4. Newly diagnosed 2019-nCOV pneumonia.",Viral nucleic acid detection;CT Scan of the Lungs;Blood routine examination;Temperature;Height;Weight;,NA,NA,NA,NA,NA,2020-02-01
1,0,NA,NA,An open labelled trial to evaluate safety and efficacy of SSV Formulation to boost immunity in quarantine patients of COVID-19,Intervention1: SSV Formulation Tablets: Each tablet of 500 mg to be consumed orally twice a day immediately after meals for 15 days.<br>Control Intervention1: Not Applicable: Not Applicable<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42967,Study of Shreepad Shree Vallabh SSV Formulation to improve immunity in quarantine patients of COVID-19,CTRI,CTRI/2020/04/024659,2020-04-15,2020-04-27,FALSE,Interventional,"Single Arm Trial
  Method of generating randomization sequence:Not Applicable  Method of allocation concealment:Not Applicable  Blinding and masking:Not Applicable",Phase 3,30,SSV Phytopharmaceuticals,India,"Health Condition 1: B342- Coronavirus infection, unspecified
",FALSE,Yes,15-04-2020,27-04-2020,2 December 2020,NA,20200415,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Samadhan Patil,NA,"Department of Medicine,
Niphad Sub district Hospital, Niphad, Maharashtra, India",yogesh_dound@yahoo.com,91-9769057549,Shreepad Shree Vallabh SSV Phytopharmaceuticals,"Inclusion criteria: 1. Recent history of contact with COVID-19 positive people and are advised to be quarantined or has symptoms which include cough, fever with or without chills and difficulty in breathing. <br/ ><br>2. Willing to provide informed consent.",Exclusion criteria: 1. Presence of acute hypoxic respiratory failure. <br/ ><br>2. Intensive care unit (ICU) stay. <br/ ><br>3. Patients who need mechanical ventilation. <br/ ><br>4. Category 6 or 5 based on modified 7-category ordinal scale of clinical status.,"Improvement in ambulatory patients who are assessed daily for symptoms which include cough, fever with or without chills and difficulty in breathing for the period they are in quarantine.    <br/ ><br> <br/ ><br>Timepoint: Baseline, telephonically everyday and day 15.",NA,28/05/2020,NA,NA,NA,2020-04-15
0,1,NA,NA,Pilot Trial for the Benefit of Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Drug: virgin coconut oil (VCO);Other: placebo,https://clinicaltrials.gov/show/NCT04594330,Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,CT.gov,NCT04594330,2020-10-05,2020-06-01,FALSE,Interventional,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",Phase 2,60,Gadjah Mada University,Indonesia,Coronavirus Infections,FALSE,Yes,05/10/2020,"June 1, 2020",2 November 2020,NA,20201005,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Recruiting,No,18 Years,N/A,All,;,"Ika Trisnawati, MD, MSc, internist;Ika Trisnawati, MD, MSc, internist",NA,;ika.trisnawati@ugm.ac.id,;6281228282801,Gadjah Mada University;,"<br>        Inclusion Criteria:<br><br>          -  Adult patients, age = 18 years old.<br><br>          -  COVID-19 patients diagnosed with nasopharyngeal/oropharyngeal PCR swab specimens that<br>             are treated in Central Public Hospital Dr. Sardjito, Teaching Hospital of Universitas<br>             Gadjah Mada (UGM), and Yogyakarta COVID-19 referral hospitals.<br><br>          -  Patients with mild and moderate pneumonia symptoms that are treated in Central Public<br>             Hospital Dr. Sardjito, Teaching Hospital of Universitas Gadjah Mada (UGM), and<br>             Yogyakarta COVID-19 referral hospitals.<br><br>        Exclusion Criteria:<br><br>          -  Patients with liver function disorder.<br><br>          -  VCO hypersensitivity.<br><br>          -  Patients with severe pneumonia and/or Acute Respiratory Distress Syndrome (ARDS).<br><br>          -  Pregnant patients.<br><br>          -  Patients with malignant comorbidity.<br><br>          -  Critical or unconscious patients.<br><br>          -  Patients using other immunomodulators similar to VCO within less than three days<br>             before VCO administration.<br>",NA,"Ordinal scale for measuring clinical improvement by the World Health Organization (WHO);Clinical symptoms improvement, determined with interview and examination;Pain as side effects of the drugs, measured by Visual Analog Scale;Allergic reaction severity in mild, moderate, or severe",NA,NA,NA,NA,NA,2020-10-05
1,0,NA,NA,"Phase II, open label, randomized controlled trial to evaluate safety 
and efficacy of ACT 12 tablet and ACT 13 dry syrup as an 
immunomodulator in adult Covid 19 positive patients",Intervention1: ACT 12 tablet and ACT 13 dry syrup: 2 tablets of ACT12 and 20 ml ACT 13 dry syrup thrice a day along with standard of care for 10 days<br>Control Intervention1: Standard treatment: Standard treatment as per<br>protocol of ICMR for 10 days<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45581,Clinical trial of ACT 12 tablet and ACT 13 dry syrup in Covid 19 patients,CTRI,CTRI/2020/07/026630,2020-07-16,2020-07-22,FALSE,Interventional,"Randomized, Parallel Group Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Case Record Numbers  Blinding and masking:Open Label",Phase 2,60,Mr Ghanshyam Goti,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,16-07-2020,22-07-2020,2 December 2020,NA,20200716,12/3/2020 5:31:55 PM,CTRI,Recruiting,No,NA,NA,NA,Dr Pawan Kumar Singh,NA,"Second floor, Cabin No. 1, Sagar Complex, Old Pune-Mumbai Road,Chinchwad, Pune",gplifehealthcare@gmail.com,9824917109,Gplife Healthcare Pvt Ltd,Inclusion criteria: Patients admitted with RT-PCR confirmed COVID-19 illness <br/ ><br>Age more than 18 & less than 65 years of either sex <br/ ><br>Mild to Moderately Covid 19 disease (NEWS score less than or equal to 8) <br/ ><br>Signed informed consent must be obtained and documented according to national/local regulations,"Exclusion criteria: Pregnant women    <br/ ><br>Breastfeeding women   <br/ ><br>Requiring ICU admission at screening   <br/ ><br>Patients above 65 years of age and below 18 Years  <br/ ><br>Past History of MI, Epileptic episodes   <br/ ><br>Any other co-morbidity (uncontrolled diabetes, severe hypertension from subject history) which  <br/ ><br>is at critical stage at screening   <br/ ><br>Any other condition by which subject proves unfit from investigator perspective  <br/ ><br>Not giving consent.","No. of days for negative PCR confirmatory test from nasopharyngeal swab for COVID 19. <br/ ><br>Change in clinical symptom presentation in Cough, breathlessness, persistent pain and pressure  <br/ ><br>in the chest, bluish discoloration of lips/ face on 5 point ordinal scale:None (1), mild (2), moderate (3), severe (4), extremely severe (5)  <br/ ><br>Serum levels of CRP, IgM, IgG. <br/ ><br>Clinical status expressed in percentage of subjects on 6 point ordinal scale.Timepoint: Screening visit, Day 0, Day 4, Day 7 and Day 10 ie end of study",NA,NA,NA,NA,NA,2020-07-16
1,0,NA,NA,Optimization Protocal of Integrated Traditional Chinese and Western Medicine Treatment for Novel Coronavirus Pneumonia (COVID-19),Group 1:Traditional Chinese Medicine prescription No. 1 and 2;Group 2:Gankeshuangqing capsule;Group 3:Shuanghuanglian oral liquid;,http://www.chictr.org.cn/showproj.aspx?proj=49770,Optimization Protocal of Integrated Traditional Chinese and Western Medicine in the Treatment for Novel Coronavirus Pneumonia (COVID-19),ChiCTR,ChiCTR2000030003,2020-02-19,2020-02-19,FALSE,Interventional study,Parallel,N/A,Group 1:120;Group 2:240;Group 3:120;,Hospital of Chengdu University of Traditional Chinese Medicine,China,Novel Coronavirus Pneumonia (COVID-19),FALSE,Yes,2020-02-19,2020-02-19,25 February 2020,NA,20200219,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,NA,NA,Both,Tang Jianyuan,NA,"39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China",tangjianyuan163@163.com,+86 13910768464,Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,"Inclusion criteria: (1) Patients with mild who are in compliance with the ""Pneumonitis Diagnosis and Treatment Program for COVID-19(Trial Fifth Edition)"" (released on 2020.2.4);<br>(2) Aged more than 18 years old;<br>(3) Informed consent of the patient.",Exclusion criteria: No,hospital stay;Discharge rate;Site-specific hospital metastasis rate or severe conversion rate;Body temperature normalization time;Clinical symptoms disappearance rate;,NA,NA,NA,NA,NA,2020-02-19
0,1,NA,NA,"Evaluation the effect of aqueous extract of licorice on coronavirus outpatients: A randomized, double-blind, placebo-controlled clinical trial","Intervention 1: Intervention group: In addition to the standard treatment regimen  for covid-19,  capsules which have aqueous licorice extract  containing 80 mg of the active ingredient glycyrrhizin will be given three times a day for 2 weeks. Licorice capsules are formulated at the Mashhad School of Pharmacy with the ineffective ingredients of Ovisil and Arozil. Intervention 2: Control group: ]n addition to general drugs for  treatment of corona, the patients take placebo capsule 3 times a day for 14 days.",http://en.irct.ir/trial/46893,Evaluation the effect of licorice for treatment of coronavirus,IRCT,IRCT20200404046933N1,2020-04-12,2020-04-20,FALSE,interventional,"Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization in three stages: 1-  Generation simple or limited randomization will be done based on a table of random numbers
2- Allocation concealment: which is done in the form of
coded boxes (numbered drug containers) with a random
sequence. In this method, a number of boxes with the
same shape and size are numbered based on random
sequences and contain drugs or placebo that have a
completely similar appearance. 3- Execution of random
allocation process: A: Identify the person who creates the
random sequence B: A person who evaluates and
registers researchers in terms of inclusion and exclusion
criteria C: The person who assigned the participants to
the groups: infectious diseases specialist The main
researcher of the project, who creates a random
sequence, does not interfere in other stages of
randomization, including registration and allocat",2,40,Mashhad University of Medical Sciences,Iran (Islamic Republic of),Covid-19. <br>Covid-19 disease;U07.1,FALSE,Yes,2020-04-12,2020-04-20,18 May 2020,NA,20200412,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,18 years,65 years,Both,Gholamreza Karimi,NA,Vakil abad Blvd,karimig@mums.ac.ir,+98 51 3180 1191,Mashhad University of Medical Sciences,"Inclusion criteria: Patients diagnosed for coronavirus according to clinic such as fever, cough and mylagia<br>Patients diagnosed for coronavirus according to paraclinic such as lymphopenia and increase of CRP<br>Patients in the range of 18-65 years old","Exclusion criteria: Sensitivity to licorice and it derivatives<br>Patients with hepato, renal or respiratory disorders<br>Patients who take cytotoxic or corticosteroid drugs<br>Nursing or pregnant women","Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Time of recovery.;Lymphopenia. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Cell counter device.;CRP level. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: CRP kit.",NA,NA,NA,NA,NA,2020-04-12
0,1,NA,NA,The effect of nebulizing Peppermint extract and Rose extract on percentage of blood oxygen saturation in patients with COVID-19,"Intervention 1: Intervention group 1 : From the beginning of treatment, patients receive Nebulizing of Peppermint extract from Barij Essence brand (15 drops in 30 cc of distilled water) daily and each time for 2 hours for 3 days. Intervention 2: Intervention group 2 : From the beginning of treatment, patients receive Nebulizing of Rose extract from Barij Essence brand (15 drops in 30 cc of distilled water) daily and each time for 2 hours for 3 days. Intervention 3: Control group: From the beginning of treatment, patients receive Nebulizing of  distilled water(30 cc) daily and each time for 2 hours for 3 days.",http://en.irct.ir/trial/48311,The effect of nebulizing Peppermint extract and Rose extract on percentage of blood oxygen saturation in patients with COVID-19,IRCT,IRCT20190131042569N5,2020-08-23,2020-06-29,FALSE,interventional,"Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Each patient who qualify for inclusion after completing the consent form is assigned by the person in charge of this process using a random number table from 1 to 60 ( 1- 20 Peppermint group, 21-40 Rose oil group and 41-60 control group) where the person is placed on one of the numbers and assigned to one of the 2 specified groups. (Simple randomization by individual using random number table), Blinding description: The person responsible for follow-up and recordings data has no information about the patient's group.",3,60,Research Department of Shahid Beheshti University of Medical Sciences,Iran (Islamic Republic of),"COVID-19. <br>COVID-19, virus identified, confirmed by laboratory testing;U07.1",FALSE,No,2020-08-23,2020-06-29,7 September 2020,NA,20200823,12/3/2020 5:31:55 PM,IRCT,Recruiting,No,30 years,60 years,Both,Nima Saeedi,NA,"No. 11, First East Ave.,  Bistochahar metri Ave., Tehran.",nimasaeedi7@yahoo.com,+98 21 2641 8939,Shahid Beheshti University of Medical Sciences,Inclusion criteria: Patients with evidence of COVID-19 in Chest CT Scan<br>Age between 30 and 60 years,Exclusion criteria: History of Asthma or Chronic Obstruction Pulmonary Disease<br>History of Allergy,"Increasing of percentage of blood oxygen saturation. Timepoint: Measurement of blood oxygen saturation percentage at the beginning of the study, the first day, the second day and the third day of treatment. Method of measurement: Pulse oximetry.",NA,NA,NA,NA,NA,2020-08-23
0,1,NA,NA,"A randomized, open label, 2 Arm, prospective study to investigate the safety and efficacy of the health supplements ImmunoSEB+ProbioSEB CSC3 as supplemental therapy in confirmed mild to moderate COVID-19 patients.",Intervention1: ImmunoSEB plus ProbioSEB CSC3: ImmunoSEB Capsule / 500 mg 2 capsule bid and <br>ProbioSEB CSC3 Capsule / 5 billion CFUs 2 Capsule OD for 14 days<br>Control Intervention1: Standard Care: standard care given as per institutional practice<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45750,Clinical trial study to investigate safety and efficacy of ImmunoSEB and ProbioSEB,CTRI,CTRI/2020/08/027168,2020-08-14,2020-08-21,FALSE,Interventional,"Randomized, Parallel Group, Multiple Arm Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:An Open list of random numbers  Blinding and masking:Open Label",N/A,60,SRV Hospital,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,14-08-2020,21-08-2020,2 December 2020,NA,20200814,12/3/2020 5:31:55 PM,CTRI,Recruiting,No,NA,NA,NA,Dr Abhay Vispute Shantaram,NA,"SRV Hospital, Dr Mandakini Parihar Marg opposite Lokmanya Tilak Terminus, Tilak Nagar, Chembur, Mumbai, Maharashtra SRV Hospital, Dr Mandakini Parihar Marg opposite Lokmanya Tilak Terminus, Tilak Nagar, Chembur, Mumbai, Maharashtra",drasv.surgiciansrv@gmail.com,NA,SRV Hospital,"Inclusion criteria: 1.Patient who provides written informed consent <br/ ><br>2.Male or non-pregnant, non-lactating female aged â?¥ 18 and â?¤ 75 years (both inclusive) <br/ ><br>3.RT-PCR confirmed diagnosis of COVID-19 <br/ ><br>4.Able to take the drug orally and comply with study procedures <br/ ><br>5.Women of childbearing potential must have a negative urine pregnancy test prior to study entry <br/ ><br> <br/ ><br>","Exclusion criteria: 1. Severe Type <br/ ><br>Respiratory distress, RRâ?¥30 times/min  <br/ ><br>Finger oxygen saturation â?¤93% in rest state  <br/ ><br>Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation FiO2 â?¤300mmHg <br/ ><br>2. Critical type: meeting any of the following criteria <br/ ><br>Respiratory failure occurs and mechanical ventilation is required  <br/ ><br>Patients go into shock <br/ ><br>ICU is needed for other organ failure. <br/ ><br>3.Patients who have received tumor immunotherapy such as PD-1/L1 CTLA4 etc. in the past 1 month, and inflammatory factor modulators such as Ulinastatin. <br/ ><br>4.other viral pneumonia <br/ ><br>5.patients who have received tumor immunotherapy in tha past one month and inflammatory factor modulators such as Ulinastatin <br/ ><br>6. patients who have received organ transplantation or surgery planning in the past 6 months <br/ ><br>7. patients who cant take food or drugs due to coma or intestinal obstruction <br/ ><br>8.Patients who have severe underlying diseases that affects survival, including uncontrolled malignant tumor with multiple metastases that cannot be resected, blood diseases, dyscrasia, active bleeding, severe malnutrition, etc <br/ ><br>9.Women subjects that are pregnant or lactating, or subjects (including male subjects) having a pregnancy plan (including plans for sperm donation or egg donation) during the study period <br/ ><br>10.Allergic to systemic enzyme supplements <br/ ><br>11.Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper limit of normal, or patients with child-Pugh grade C cirrhosis <br/ ><br>12.ECLS (ECMO, ECCO2R, RRT) <br/ ><br>13.Imminent death in the opinion of the clinical team <br/ ><br>14.Patients who have participated in any other clinical study within 2 weeks prior to randomization <br/ ><br>15.15.	The investigator concludes that the patient is not suitable for the study <br/ ><br>",Proportion of patients showing clinical improvementTimepoint: Proportion of patients showing clinical improvement time frame day 14 from the baseline visit,NA,NA,NA,NA,NA,2020-08-14
0,1,NA,NA,Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis / Plasmaféresis terapéutica en Pacientes Adultos críticamente Enfermos Con diagnóstico Confirmado de COVID-19,Biological: Convalescent plasma,https://clinicaltrials.gov/show/NCT04480632,Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis,CT.gov,NCT04480632,2020-07-17,2020-08-01,FALSE,Interventional,Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Phase 2,44,Fundación Cardiovascular de Colombia,Colombia,COVID-19,FALSE,Yes,17/07/2020,"August 1, 2020",3 August 2020,PLASMA,20200717,12/3/2020 5:31:55 PM,ClinicalTrials.gov,Not recruiting,No,18 Years,N/A,All,;,"Norma Serrano, MD;Norma Serrano, MD",NA,;normaserrano@fcv.org,;3102740099,"Research, development and innovation director;","<br>        Inclusion Criteria:<br><br>          -  Age range: Over 18 years old<br><br>          -  Patients with confirmed infection by COVID-19 (positive real-time PCR) in ICU with:<br><br>          -  Respiratory failure receiving ventilatory support and high parameters<br><br>          -  Severe pneumonia with rapid progression<br><br>          -  Ability to sign informed consent<br><br>        Exclusion Criteria:<br><br>          -  Pregnant women<br><br>          -  Contraindication of plasma administration due to history of anaphylaxis during<br>             transfusions<br>",NA,In-hospital mortality,NA,NA,NA,NA,NA,2020-07-17
1,0,NA,NA,"Assessment of efficacy and safety of Ayurvedic drug combination 
in preventing the progression of severity of the disease in asymptomatic and mild symptomatic cases of COVID-19: A randomised controlled trial
",Intervention1: MSL: 	Mahasudarshan Ghana vati  - 500 mg thrice daily after meal<br>	Samsamani vati                    - 500gm thrice daily after meal<br>	Lavangadi vati                      - 500mg thrice daily after meal to be chewed.<br>the dose to be given for 10 days<br>Control Intervention1: Standard of Care 	: State Guidelines for the management of asymptomatic and mild cases of COVID-19 for 10 days<br>,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45846,An interventional study to access the effect of Ayurvedic medicine in positive cases of COVID-19.,CTRI,CTRI/2020/08/027040,2020-08-08,2020-08-12,FALSE,Interventional,"Randomized, Parallel Group Trial
  Method of generating randomization sequence:Computer generated randomization  Method of allocation concealment:Not Applicable  Blinding and masking:Open Label",Phase 3,200,Ministry of AYUSH,India,"Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
",FALSE,Yes,08-08-2020,12-08-2020,2 December 2020,NA,20200808,12/3/2020 5:31:55 PM,CTRI,Not Recruiting,No,NA,NA,NA,Dr Bishnu Choudhury,NA,"Department of Kayachikitsa
College of Ayurveda Mawdiangdiang",drbishnuchoudhury@gmail.com,9401597062,North Eastern Institute of ayurveda and homoeopathy,"Inclusion criteria: 1. Individuals of either sex above the age of 15 years to 65 years. <br/ ><br>2. Subjects testing positive for SARS CoV-2 by RT-PCR, presenting with no symptoms or mild symptoms (as defined by US-CDC). <br/ ><br>3. Subjects who are ready to provide written/digital informed consent and who are willing to participate and follow the protocol requirements of the clinical study","Exclusion criteria: 1. Cases of COVID-19 with clinical severity ranging from moderate to critical (as defined by US-CDC). <br/ ><br>2. Pregnant and Lactating females. <br/ ><br>3. Subjects having uncontrolled and unstable co morbidities. <br/ ><br>4. Immunocompromised subjects or those taking any kind of immunosuppressive therapy. <br/ ><br>5. COVID-19 positive cases participating as subjects in other COVID-19 clinical trials. <br/ ><br>6. Subjects having a past history of allergy to any medicine that is part of the Ayurvedic intervention. Other conditions, which in the opinion of the investigators, makes the patient unsuitable for enrolment or could interfere with his participation in, and completion of the protocol.","1)	To assess the effectiveness of Ayurvedic fixed drug combination (Mahasudarshan ghana vati, Samsamani vati and Lavangadi vati) in preventing the progression of severity of the disease in SARS-CoV 2 tested positive asymptomatic and mild cases of COVID-19.Timepoint: 3 months",NA,NA,NA,NA,NA,2020-08-08
1,0,NA,NA,Clinical Research on Treatment of COVID-19 (mild and moderate cases) with Toujiequwen Granules,experimental group:Toujiequwen Granules and basic treatment ;control group:basic treatment with or without antiviral therapy ;,http://www.chictr.org.cn/showproj.aspx?proj=51136,A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19),ChiCTR,ChiCTR2000031089,2020-03-22,2020-03-13,FALSE,Interventional study,Non randomized control,N/A,experimental group:150;control group:150;,Guangzhou Eighth People's Hospital,China,COVID-19,FALSE,No,2020-03-22,2020-03-13,23 March 2020,NA,20200322,12/3/2020 5:31:55 PM,ChiCTR,Not Recruiting,No,18,80,Both,Luping Lin,NA,"627 Dongfeng Road, Yuexiu District, Guangzhou, Guangdong, China",13533550083@163.com,+86 13533550083,Guangzhou Eighth People's Hospital,"Inclusion criteria: 1. Patients who have been diagnosed as COVID-19 according to The Diagnosis and Treatment Plan for 2019-nCoV(The Fifth Trial Edition);<br>2. aged between 18 to 80 years old, male or female;<br>3. the subjects participating the clinical trial are voluntary and sign the informed consent, thoroughly informed the purpose, method, possible reaction.","Exclusion criteria: 1. Patients who are difficult to be administered orally or by nasal feeding, those who are allergic to the test drug and those who are intolerant to the drug;<br>2. The compliance of medication cannot be guaranteed during the treatment<br>3. Patients with severe primary respiratory diseases, or pneumonia caused by other pathogen.<br>4. Patients with serious diseases, malignant tumors or mental diseases;<br>5. Pregnant women, urine pregnancy test positive;<br>6. Participated in other drug trials in the past month;<br>7. The investigator judged that the patient was not suitable for the study.",syndrome;nucleic acid of nCoV-19;,NA,NA,NA,NA,NA,2020-03-22
